| Excerpt | Reference |
|---|
| "One hundred patients, 54 with acute myelogenous leukemia (AML) and 46 with acute lymphoblastic leukemia (ALL), considered to be in the end stages of their disease, after combination chemotherapy were treated by marrow transplantation." | ( Banaji, M; Buckner, CD; Clift, RA; Fefer, A; Flournoy, N; Goodell, BW; Hickman, RO; Lerner, KG; Neiman, PE; Sale, GE; Sanders, JE; Singer, J; Stevens, M; Storb, R; Thomas, ED; Weiden, PL, 1977) |
| "Problems of maintaining therapy for acute myelocytic leukemias in adults are discussed." | ( Gürtler, R; Raderecht, C, 1975) |
| "A 13-year-old boy with acute myelogenous leukemia resistant to conventional chemotherapy received a bone marrow transplant from his HL-A-identical, mixed lymphocyte culture-reactive sister." | ( Gale, RP; Opelz, G; Sparkes, R, 1975) |
| "One patient with previously treated acute myelocytic leukemia was induced into a good partial remission lasting 10 weeks." | ( Cuttner, J; Holland, JF; Nogeire, C; Ohnuma, T, 1978) |
| "In 14 patients with acute myeloid leukemia (AML) the plasma concentration of cytosine arabinoside (Ara-C) was determined at the start of the first course of treatment at various intervals after a bolus injection." | ( Haanen, C; van der Kleijn, E; van Prooijen, R, 1977) |
| "Children with acute myelogenous leukemia had normal lysozyme levels, while children with monomyelocytic leukemia had substantially elevated lysozyme levels before treatment." | ( Bratlid, D; Moe, PJ, 1978) |
| "The response of an acute myeloid leukemia in a rat model to ADR was not affected by this pretreatment." | ( Sonneveld, P, 1978) |
| "A 51-year-old woman had acute myelogenous leukemia following log-term cyclophosphamide therapy for rheumatoid arthritis." | ( Kapadia, SB; Kaplan, SS, 1978) |
| "However, in the acute myeloblastic leukemia, a significantly higher frequency of infection during or after the induction treatment was observed in the cases presenting initially without a raised serum lysozyme level." | ( Bilski-Pasquier, G; Cadiou, M; Garand, R; Pillon-Hardy, ME; Zittoun, J; Zittoun, R, 1979) |
| "Rapidly fatal acute myelogenous leukemia (AML) occurred in a woman with advanced (Stage III) ovarian carcinoma who was treated with thiotepa for 30 months." | ( Kapadia, SB; Krause, JR, 1978) |
| "Cytarabine and thioguanine therapy for acute myelocytic leukemia, initiated during the 26th week of pregnancy, led to complete remission of the leukemia in a 22-year-old woman, and allowed for delivery of a normal infant at term." | ( Curet, LB; Raich, PC, 1975) |
| "Eighteen children with acute myeloid leukemia have been treated with a four-drug protocol using cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine." | ( Evans, DI; Jones, PH; Morley, CJ, 1975) |
| "Thirty-seven adults with acute myelogenous leukemia (AML) were treated with a combination of daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) for remission induction." | ( Hirano, M; Imai, K; Imamura, K; Ishiguro, J; Kamiya, T; Koie, K; Nishiwaki, H; Ohno, R; Sako, F; Uetani, T, 1975) |
| "In a patient with acute myelogenous leukemia infected with Plasmodium vivax, neither his underlying disease nor intensive cytotoxic chemotherapy appeared to ameliorate or worsen the clinical course of his infection." | ( Armstrong, D; Tapper, ML, 1976) |
| "Out of 32 adult patients with ANLL treated with DCMP regime 26 (81." | ( Liong, SK; Uzuka, Y; Yamagata, S, 1976) |
| "During the course of treatment for acute myelocytic leukemia, Haemophilus aphrophilus was isolated from eight blood cultures associated with the clinical picture of bacterial endocarditis." | ( Bennett, JM; Enck, RE, 1976) |
| "Sixty-six newly diagnosed patients with acute nonlymphocytic leukemia received either daunorubicin alone or a combination of daunorubicin, cytosine arabinoside, 6-thioguanine, and pyrimethamine for remission-induction therapy." | ( Aisner, J; Fortner, C; Lichtenfeld, JL; O'Connell, MJ; Schiffer, CA; Schimpff, SC; Wiernik, PH, 1976) |
| "Eighteen cases of ANLL have been studied on admission, before chemotherapy was started." | ( García Avello, A; García Frade, LJ; García Laraña, J; Sureda, A; Torrado, MC, 1992) |
| "Forty-eight patients with acute myelogenous leukemia (AML) not eligible for anthracycline or mitoxantrone treatment, mostly due to cardiac contraindications, were given aggressive therapy using m-amsacrine (AMSA) in combination with conventional or high-dose cytarabine for remission induction." | ( Heit, W; Maschmeyer, G; Willborn, K, 1992) |
| "6 cases of ANLL M3 type were treated with trans-retinoic acid and all had CR." | ( , 1992) |
| "We describe a case of acute nonlymphocytic leukemia with inversion of chromosome 16 in a patient with systemic lupus erythematosus treated with immunosuppressive agents including azathioprine and cyclophosphamide." | ( Kavanaugh, AF; Lipsky, PE; Schneider, NR; Vasquez, S; Wacholtz, MC, 1992) |
| "As salvage therapy for relapsed ANLL etoposide produces 28% complete responses in combination with amsacrine, 49% with 5-azacytidine, and 51% with anthracycline." | ( Bishop, JF, 1992) |
| "A girl with acute myelogenous leukemia (AML) was treated with high dose arabinoside cytosine during consolidation." | ( Balcar-Boroń, A; Nowaczyk-Michalak, A; Pilecki, O; Trybuś, L; Wysocki, M, 1992) |
| "Therapy for acute myelogenous leukemia includes remission induction and consolidation with an array of antineoplastic agents." | ( McCauley, DL, 1992) |
| "Thirty adult patients with acute myelogenous leukemia (AML) in remission were treated with hyperfractionated total body irradiation, VP-16, and cyclophosphamide followed by infusion of autologous bone marrow purged with 4-hydroperoxycyclophosphamide and VP-16." | ( Acaba, L; Atzpodien, J; Berman, E; Clarkson, B; Crown, J; Doherty, M; Gulati, S; Motzer, R; Reich, L; Yahalom, J, 1992) |
| "In a pilot study, five adults with acute myeloid leukemia were treated with the new immunomodulator Linomide post-ABMT." | ( Bengtsson, M; Carlsson, K; Nilsson, B; Oberg, G; Simonsson, B; Smedmyr, B; Termander, B; Tötterman, TH, 1992) |
| "Since January 1988, 91 children with ANLL have been treated with a polychemotherapy regimen containing Mitoxantrone (MTZ), excluding other anthracyclines." | ( Babin, A; Béhar, C; Bertrand, Y; Boutard, P; Brock, P; Robert, A; Rubie, H; Solbu, G; Suciu, S; Vilmer, E, 1992) |
| "The risk of acute nonlymphocytic leukemia was significantly increased after regional radiotherapy alone (relative risk, 2." | ( Bernstein, L; Boice, JD; Curtis, RE; Flannery, JT; Greenberg, RS; Hoover, RN; Moloney, WC; Schwartz, AG; Stovall, M; Weyer, P, 1992) |
| "Acute nonlymphocytic leukemia (ANLL) developed in 2 of 142 pediatric patients with osteosarcoma treated with a cis-diamminedichloroplatinum-II (CDP)-based regimen: acute monomyelogenous leukemia (M4) with a normal female karyotype in one and acute myelogenous leukemia (M2) with t (8,21) in the other." | ( Jaffe, N; Jeha, S; Robertson, R, 1992) |
| "Despite substantial progress in the treatment of acute myeloid leukemia (AML), fewer than 25% of patients survive free of leukemia for more than 5 years without allogeneic bone marrow transplantation (BMT)." | ( Champlin, RE; Gajewski, JL; Ho, WG; Nimer, SD; Schiller, GJ; Territo, MC, 1992) |
| "Twenty-seven patients with acute myelogenous leukemia (AML), aged 15 to 65 years, were treated with standard induction remission chemotherapy and two different strategies for postremission treatment." | ( Intragumtornchai, T; Mahasandhana, S; Sucharitchan, P; Swasdikul, D; Watananukul, P, 1991) |
| "Thirty-one children with ANLL were treated using the 12th-ANLL Protocol of the Tokyo Children's Cancer Study Group incorporating an ACMP 2-step regimen." | ( Bessho, F; Kigasawa, H; Nakazawa, S; Ohkawa, Y; Sugita, K; Tsuchida, M; Tsukimoto, I; Tsunematsu, Y; Yamada, K; Yamamoto, M, 1991) |
| "Five patients with ANLL (4 with ANLL-M3 and one with ANLL-M2) were treated with retinol palmitate." | ( Nakamura, T; Tsutani, H; Uchida, M; Ueda, T, 1991) |
| "Twenty-five patients with acute nonlymphoblastic leukemia undergoing 41 cycles of chemotherapy with daunorubicin/cytosine arabinoside (ara-C) or with etoposide/ara-C received metoclopramide (MCP; 0." | ( Advani, SH; Banavali, SD; Charak, BS; Gopal, R; Iyer, RS; Saikia, TK, 1991) |
| "A 36-year-old female with hypoplastic acute myelogenous leukemia was treated with this atypical leukemias." | ( Fukushima, T; Kamiyama, N; Kanzaki, A; Ohtsuki, T; Shirato, L; Toyota, E; Yamada, O; Yawata, Y, 1991) |
| "Previously untreated ANLL patients 15 to 70 years of age were randomly assigned to cytarabine (100 mg/m2) on days 1 to 7 plus daunorubicin (50 mg/m2) on days 1 to 3 (7-3) or to the same drugs plus etoposide (75 mg/m2) on days 1 to 7 (7-3-7)." | ( Bishop, JF; Cooper, IA; Joshua, D; Lowethal, R; Matthews, JP; Wolf, MM, 1991) |
| "Etoposide is active in ANLL and prolongs remission when used as induction therapy." | ( Bishop, JF, 1991) |
| "Finally, patients with acute myeloid leukemias were studied before and 24 h after therapy with a daunomycin containing regimen." | ( Guo, WJ; Masterson, M; Mayers, GL; Mehdi, I; Mirto, S; Motyka, LE; Raza, A; Yousuf, N, 1991) |
| "To determine its activity in acute myelogenous leukemia (AML), 130 consecutive adult patients between the ages of 16 and 60 with newly diagnosed disease were randomized in a single institution study to receive either IDR in combination with cytosine arabinoside (Ara-C) or standard therapy with daunorubicin (DNR) and Ara-C." | ( Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, S; Kolitz, J; McKenzie, S; Santorsa, J, 1991) |
| "A 25-year-old woman was diagnosed as acute myeloblastic leukemia (M1 in FAB classification) in May 1983, and treated with DCMP regimen, which led to the complete remission." | ( Fujita, N; Gotoh, H; Inaba, T; Itoh, K; Murakami, S; Nakagawa, M; Nakanishi, S; Oku, N; Shimazaki, C, 1991) |
| "Forty-eight patients with acute nonlymphocytic leukemia (ANLL) and myelodysplastic syndromes (MDS) were treated with low-dose Ara-C regimen (LDAC) (10 mg/m2 or 10 mg/body subcutaneously every 12 hours)." | ( Fukawa, H; Harano, H; Hashimoto, Y; Kanamori, H; Kodama, F; Maruta, A; Matsuzaki, M; Miyashita, H; Murata, T; Noguchi, T, 1991) |
| "Thirty-two patients with refractory acute myeloid leukemia (AML) received salvage therapy with a single course of mitoxantrone 6 mg/m2 intravenous (IV) bolus, etoposide 80 mg/m2 IV for a period of 1 hour, and cytarabine (Ara-C) 1 g/m2 IV for a period of 6 hours daily for 6 days (MEC)." | ( Amadori, S; Arcese, W; Isacchi, G; Mandelli, F; Meloni, G; Monarca, B; Petti, MC; Testi, AM, 1991) |
| "A case of acute nonlymphocytic leukemia (ANLL) following chemotherapy with cisplatin (CDDP) and etoposide (VP16) for non-small-cell lung cancer (NSCLC) diagnosed 24 months before is reported." | ( Brenez, D; Devriendt, J; Lenclud, C; Schmerber, J, 1990) |
| "In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment." | ( Appelt, M; Büchner, T; Eichelbaum, M; Grille, W; Hiddemann, W; Hossfeld, DK; Koslowski, B; Kraft, J; Kuse, R; Quabeck, K, 1990) |
| "A study of treated murine acute myeloid leukemia (AML) with an emphasis on the bone marrow stromal function is reported." | ( Ben-Ishay, Z; Prindull, G; Sharon, S; Yankelev, S, 1990) |
| "Adult acute myelocytic leukemia (AML) is a curable disease in responsive patients with aggressive treatment in remission." | ( Burke, PJ; Geller, RB; Karp, JE; Santos, GW; Saral, R, 1990) |
| "In patients with acute myeloblastic leukemia incomplete response to induction chemotherapy and short disease-free survival may be related to cell kinetic quiescence of leukemic cells." | ( Andreeff, M; Tafuri, A, 1990) |
| "A diagnosis of ANLL was made and a hematological remission was obtained after one course of combination chemotherapy consisting of BH-AC, daunorubicin and prednisolone, but the enlarged mediastinal tumor and pulmonary infiltration worsened rapidly followed by marked dyspnea." | ( Ashihara, K; Kimura, S; Kobayashi, Y; Kondo, M; Kuritsuka, H; Maruo, N; Ozawa, M; Sawada, M; Setoguchi, J; Wada, K, 1990) |
| "A 36-year-old man with acute myelogenous leukemia, refractory to the combination chemotherapy, developed fungal infection and acute respiratory distress." | ( Itou, S; Koyama, S; Shibata, A, 1990) |
| "Seven patients with acute myeloid leukemia (AML) in first complete remission were treated with escalating high doses of cyclophosphamide, etoposide, and cytosine arabinoside (Ara-C)." | ( Havemann, K; Koeppler, H; Pflueger, KH; Weide, R; Wolf, M, 1990) |
| "26 patients with poor risk acute myelogenous leukemia (elderly, in relapse or resistant) were treated with a combination of oral idarubicin (30 mg/m2/d for 3 days) and low dose subcutaneous cytarabine (10 mg/m2 twice a day for 10 days)." | ( Chapuis, B; Grob, JP; Helg, C; Pugin, P, 1990) |
| "Forty-one children with refractory acute nonlymphocytic leukemia (ANLL) were treated from March 1975 to February 1979 with a schedule-dependent combination of methotrexate (MTX) and L-asparaginase." | ( Dahl, GV; Hudson, MM; Kalwinsky, DK; Pui, CH, 1990) |
| "Therapy of acute myelogenous leukemia (AML) with sequential high-dose ara-C and asparaginase (HiDAC----ASNase) on a day 1 and 8 schedule was designed to exploit potential recruitment of residual leukemia cells following initial cytoreduction from day 1 treatment." | ( Capizzi, RL; Contento, MM; Craig, JB; Do, KA; Gregory, BW; Kute, TE; Lyerly, ES; Powell, BL, 1990) |
| "91 patients with acute nonlymphoblastic leukemia (ANLL) were treated with Homoharringtonine, Cytosine arabinnoside, Thioguanine (HAT) and/or Daunorubicin, (Adriamycin) Cytosine arabinnoside, Thioguanine D(A) AT protocols." | ( Bian, SG; Hao, YS; Wang, ZC, 1990) |
| "Previously untreated patients with acute nonlymphocytic leukemia (ANLL) aged 15 to 70 years were randomized to either cytosine arabinoside 100 mg/m2/d continuous intravenous (IV) infusion days 1 through 7, daunorubicin 50 mg/m2/d IV days 1 through 3 (7-3), or the same drugs intensified with etoposide 75 mg/m2/d IV days 1 through 7 (7-3-7) as induction therapy." | ( Bishop, JF; Cobcroft, R; Dodds, A; Joshua, D; Kronenberg, H; Lowenthal, RM; Ma, D; Matthews, JP; Todd, D; Whiteside, MG, 1990) |
| "Thirty-nine patients with acute myeloblastic leukemia (AML) in first complete remission (CR) were treated by autologous bone marrow transplantation." | ( Carella, AM; De Fabritiis, P; Mandelli, F; Mangoni, L; Marmont, A; Meloni, G; Porcellini, A, 1990) |
| "Five cases of hypoplastic acute myelocytic leukemia were treated with an IgG-melphalan conjugate, K-18." | ( Inagaki, N; Nakada, H; Nonaka, K; Ohmoto, E; Osada, K; Takahashi, I; Takeuchi, M; Tsurumi, N; Uchida, K; Yorimitsu, S, 1988) |
| "We describe a patient with acute nonlymphocytic leukemia in whom chromosomal analysis showed a 8,21(q22;q22) translocation and who entered complete remission after one course of chemotherapy." | ( Bernasconi, C; Bernasconi, P; Bonfichi, M; Castagnola, C; Colombo, A, 1989) |
| "Two patients of acute myeloblastic leukemia (M2) with post-transfusional hepatitis (non-A, non-B) were treated with alpha-IFN and high-dose SNMC before allogeneic bone marrow transplantation." | ( Fujimoto, H; Fukuhara, T; Hashino, S; Imamura, M; Karino, Y; Kobayashi, H; Matsushima, T; Sakurada, K; Tanaka, M; Yoshida, J, 1989) |
| "A total of 23 patients with high-risk acute myelogenous leukemia (AML) at diagnosis (2 patients), relapsing AML (14) or resistant AML (6) were treated with 25 micrograms/kg i." | ( Archimbaud, E; Devaux, Y; Fiere, D; French, M; Guyotat, D; Moriceau, M; Sebban, C; Troncy, J; Viala, JJ, 1989) |
| "We reported a 68-year-old woman with acute nonlymphocytic leukemia, in whom the leukemia transformed from poorly differentiated myeloperoxidase (MPO)-negative type into myelomonocytic type during the observation without chemotherapy." | ( Enokihara, H; Furusawa, S; Hamaguchi, H; Saito, K; Sakamaki, H; Shishido, H; Suzuki, T; Watanabe, K; Watanabe, N; Yoshida, M, 1989) |
| "Thirty-four consecutive adults with ANLL were treated with an intensified induction regimen and a high dose sequential postremission therapy consisting of daunomycin, Ara-C, 6-MP and prednisolone (DCMP)." | ( Saito, Y; Uzuka, Y, 1989) |
| "In 3 patients with ANLL, chemotherapy including high or conventional doses of Ara-C had been ineffective." | ( Avalos, M; Brivet, F; Dommergues, JP; Léonard, C; Miélot, F; Mirica, C; Tchernia, G; Tertian, G, 1989) |
| "A patient with acute myeloid leukemia received bromodeoxyuridine (BrdU) prior to remission induction therapy." | ( Gezer, S; Mehdi, I; Preisler, HD; Raza, A, 1989) |
| "A patient with acute myeloblastic leukemia received high-dose busulfan (1 mg/kg by mouth every 6 h for 4 days) as myelo-ablative therapy for autologous bone marrow transplantation." | ( Ehrsson, H; Hassan, M; Oberg, G; Simonsson, B; Smedmyr, B; Tötterman, T; Wallin, I, 1989) |
| "Twenty-four patients with acute nonlymphocytic leukemia (ANLL) were treated with high-dose chemotherapy or chemoradiotherapy followed by infusion of autologous marrow purged with 100 micrograms/mL of 4-hydroperoxycyclophosphamide (4HC)." | ( Colvin, M; Mangan, KF; Przepiorka, D; Rosenfeld, C; Shadduck, RK, 1989) |
| "Since 1980, adults with acute myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy." | ( Braine, HG; Burke, PJ; Fox, MG; Geller, RB; Hall, KL; Humphrey, RL; Karp, JE; Morrell, L; Tucker, RW; Zahurak, M, 1989) |
| "Seventeen elderly patients with acute nonlymphocytic leukemia (EP-ANLL) were treated with cytarabine, either 1." | ( Bennett, JM; Cassileth, P; Ebrahim, K; Kahn, SB; Knospe, WH; O'Connell, MJ, 1989) |
| "A 20-month-old child was treated for acute nonlymphocytic leukemia (ANLL) with basophilic differentiation." | ( Akiyama, Y; Kubota, M; Mikawa, H; Tabata, Y; Yoshigi, M, 1989) |
| "Sixteen adults with acute myelogenous leukemia (AML) in relapse or refractory to conventional therapy were treated with AB-Triple V therapy." | ( Akagi, K; Asou, N; Goto, J; Hamasaki, N; Hidaka, M; Kawano, F; Kurisaki, H; Sawatari, T; Suzushima, H; Takatsuki, K, 1989) |
| "One hundred ninety-six patients with acute myelogenous leukemia (AML) were treated with intensive induction chemotherapy using similar daunorubicin/cytarabine/thioguanine regimens." | ( Champlin, RE; Gajewski, JL; Gekelman, L; Hirji, KF; Ho, WG; Jacobs, AD; Nimer, SD, 1989) |
| "Eight patients with acute nonlymphoblastic leukemia were treated with a combination of daunorubicin (1." | ( Liliemark, J; Paul, C; Peterson, C; Tidefelt, U, 1989) |
| "Two patients with acute nonlymphocytic leukemia (ANLL) developed peripheral motor and sensory neuropathies after consolidation chemotherapy with high-dose cytosine arabinoside (ara-C), daunorubicin, and asparaginase." | ( Capizzi, RL; Cooper, MR; Lyerly, ES; Powell, BL, 1986) |
| "Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT)." | ( Burns, WH; Geller, RB; Santos, GW; Saral, R; Vogelsang, GB; Wingard, JR; Yeager, AM, 1988) |
| "Using leukemic cells from acute myelocytic leukemia patients with or without treatment, similar results were obtained." | ( Katabami, F; Katoh, N; Kimura, K; Koyama, M; Miyazaki, T; Sakurada, K; Uehara, Y; Yamabe, M, 1985) |
| "A 35-year-old woman relapsing from acute myeloid leukemia (AML) after a bone marrow transplantation (BMT) achieved complete remission by low dose Ara-C treatment." | ( Gerhartz, HH; Kolb, HJ; Mittermüller, J; Wilmanns, W, 1985) |
| "Thirty-five patients with acute myelogenous leukemia were treated with aclacinomycin A (60 mg/m2/day for 5 days) and VP-16-213 (100 mg/m2/day for 5 days)." | ( Bennett, JM; Chang, AY; Rowe, JM, 1988) |
| "Sixteen patients with previously treated acute nonlymphocytic leukemia or chronic myelogenous leukemia in blast crisis were given one to three courses of esorubicin by continuous infusion over 48 h." | ( Allen, SL; Budman, DR; Chan, K; Kreis, W; Rottach, C; Schulman, P; Vinciguerra, V; Weiselberg, L, 1988) |
| "Eighty-seven children with acute nonlymphoblastic leukemia were treated with the AML protocol BFM 78 between June 1979 and February 1986 in a multicenter study in the GDR." | ( Dörffel, W; Eggers, G; Exadaktylos, P; Fuchs, D; Hermann, J; Hilgenfeld, E; Kotte, W; Malke, H; Plenert, W; Zintl, F, 1987) |
| "Seventy-five patients with acute nonlymphoblastic leukemia (ANL) in first remission were treated with cyclophosphamide, 60 mg/kg on each of two consecutive days followed by total body irradiation (TBI) at an exposure rate of 4-6 cGy/min from two opposing 60Co sources." | ( Appelbaum, FR; Buckner, CD; Clift, RA; Deeg, HJ; Doney, K; Sanders, JE; Storb, R; Sullivan, KM; Thomas, ED; Witherspoon, RP, 1986) |
| "Ph-positive acute myeloblastic leukemia (AML) developing in a treated case of Wegener's granulomatosis is reported." | ( Kocova, M; Ohyashiki, K; Rowe, JM; Ryan, DH; Sandberg, AA, 1986) |
| "A woman in complete remission from acute myeloblastic leukemia developed thrombotic thrombocytopenic purpura (TTP) subsequent to the third intensive consolidation cycle of cytosine arabinoside and daunorubicin chemotherapy." | ( Baquerizo, H; Byrnes, JJ; Gonzalez, M; Hensely, GT, 1986) |
| "Thirty-seven patients with acute myeloid leukemia in relapse or at initial diagnosis but resistant to conventional induction regimen have been treated by single-cycle timed sequential chemotherapy, including continuous infusion of cytarabine over 72 hours on Days 1-3 and 8-10 and short injections of daunorubicin on Days 1-3." | ( Archimbaud, E; Bryon, PA; Campos, L; Coiffier, B; Extra, JM; Fière, D; Guyotat, D; Milan, JJ; Van, HV; Viala, JJ, 1986) |
| "The Authors present a case of acute myeloblastic leukemia secondary to a busulfan and splenic radiotherapy treated idiopathic myelofibrosis." | ( Bartolomei, P; Bortotto, L; Fossaluzza, V; Tosato, F, 1986) |
| "A patient with acute myelogenous leukemia in relapse developed reversible bilateral lateral rectus muscle palsy and cerebellar dysfunction after receiving chemotherapy with high-dose cytosine arabinoside and mitoxantrone." | ( Castellanos, AM; Glass, JP; Keating, MJ; Ventura, GJ, 1986) |
| "A 69-year-old man with acute myeloblastic leukemia was admitted to the hospital for induction chemotherapy." | ( Matsuda, T; Matsumoto, T, 1986) |
| "The patient who developed acute myelogenous leukemia was asymptomatic at the time of diagnosis of ET but was treated because his platelet count was greater than 1,000,000/mm3." | ( Curtis, JL; Levin, J; Sedlacek, SM; Weintraub, J, 1986) |
| "Ten patients with acute myeloid leukemia were treated with a high-dose ara-c regimen (3 g twice daily for 6 days)." | ( Fehr, J; Gmür, J; Hofmann, V; Honegger, HP; Morant, R; Sauter, C, 1986) |
| "Thirty-eight patients with acute myeloid leukemia (AML) were treated with mitoxantrone (Mto) combined with cytarabine (Ara-C)." | ( Brito-Babapulle, F; Catovsky, D; Galton, DA; Goldman, JM; Marcus, RE; Newland, AC; Slocombe, G, 1987) |
| "Four patients with acute myeloid leukemia (AML) and three with myelodysplastic syndrome (MDS) were given low dose cytosine arabinoside (Ara-C) therapy." | ( Katayama, N; Minami, N; Shirakawa, S; Tanaka, I, 1987) |
| "A patient with refractory acute myeloid leukemia was treated with tiazofurin, an agent that causes inhibition of tumor cell proliferation by depressing GTP concentrations in the malignant cells." | ( Hoffman, R; Jayaram, HN; Lapis, E; Nichols, CR; Pennington, K; Tricot, GJ; Weber, G, 1987) |
| "Twenty-one adult patients with acute myeloid leukemia (AML) were treated with the EORTC LAM-6 remission induction protocol [daunorubicin (DNR) (45 mg/m2, days 1-3), cytarabine (200 mg/m2, days 1-7) and vincristine (1 mg/m2, day 2)]." | ( Kokenberg, E; Löwenberg, B; Nooter, K; Sonneveld, P; van der Steuijt, K, 1987) |
| "Five children with M4 or M5 acute myelogenous leukemia (AML) not responding to previous treatment or in relapse were treated with a four-drug protocol consisting of cyclophosphamide, adriamycin, vincristine, prednisone, and CNS prophylaxis." | ( Podraza, W; Urasiński, T, 1987) |
| "Five children treated for acute myeloid leukemia according to the BFM protocol AML 83 experienced first bone marrow relapse after 7, 10, 14, 18, and 30 months and were retreated for second remission induction." | ( Berthold, F; Creutzig, U; Lampert, F, 1987) |
| "Twenty-nine adult patients with acute myelogenous leukemia AML who received 40 treatment courses with high dose cytosine arabinoside (HD-A), alone or combined with other cytotoxic drugs, for remission induction (RI) or postremission intensive consolidation (IC) were retrospectively analysed for types and severity of infectious complications." | ( Kern, W; Kurrle, E; Vanek, E, 1987) |
| "Two children with acute myeloid leukemia (FAB M1 and M2) experienced bone marrow relapse during maintenance chemotherapy 7 and 10 months after diagnosis." | ( Berthold, F; Harbott, J; Lampert, F; Ludwig, WD, 1987) |
| "Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine (3 g/m2 every 12 hours for 6 days) or amsacrine (75 mg/m2 daily for 7 days)." | ( Brennan, J; Browman, G; Goldberg, J; Gottlieb, AJ; Grunwald, H; Miller, KB; Preisler, HD; Rai, K; Vogler, WR; Winton, EF, 1986) |
| "175 patients with acute myeloid leukemia were treated between February 1980 and March 1985 with a TAD-induction therapy, three intensified consolidation cycles (COAP, COAP, AD), and a two-year mild maintenance therapy." | ( Frauer, HM; Heil, G; Heimpel, H; Hoelzer, D; Kurrle, E; Link, H; Ostendorf, P; Waller, HD; Wilms, K, 1986) |
| "We treated 47 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and blastic phase of chronic myelogenous leukemia (CML) with a combination of amsacrine and HiDAc." | ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
| "In a phase I-II trial, 38 patients with acute myeloid leukemia (AML) were given single drug induction therapy with aclarubicin (ACM) according to two dosing schedules: treatment 1: 10 to 30 mg/m2/d to a maximum total dose of 300 mg/m2 or until development of unacceptable toxicity: treatment 2: 15 mg/m2/d in ten-day courses separated by ten-day intervals." | ( Benavides, M; Delgado, M; Gastiaburu, J; Goldschmidt, E; Machover, D; Mathe, G; Misset, JL; Vandenbulcke, JM, 1987) |
| "Children with acute myelogenous leukemia (AML), solid tumors and malignant lymphomas had higher lysozyme concentration before therapy than healthy children." | ( Dick, W; Dopfer, R, 1985) |
| "A new case is reported here of acute myeloid leukemia after chlorambucil therapy for multiple sclerosis." | ( Aymard, JP; Barroche, G; Conroy, T; Humbert, JC; Lederlin, P; Streiff, F; Witz, F, 1985) |
| "Patients with acute myeloid leukemia (AML) secondary to myelodysplastic phase respond poorly to standard chemotherapy designed for AML." | ( Ho, AD; Hunstein, W; Schwarz, CE, 1985) |
| "Fifty-one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L-12 protocol." | ( Arlin, Z; Burchenal, JH; Clarkson, B; Comacho, E; Dowling, M; Drapkin, RL; Dufour, P; Gee, TS; Kempin, S; McKenzie, S; Mertelsmann, R; Oettgen, HF; Passe, S; Thaler, HT; To, L, 1981) |
| "5 children with acute nonlymphocytic leukemia in relapse who had received 5-azacytidine as a part of previous multiagent chemotherapy received continuous infusion of 5-azacytidine, 150-200 mg/m2/day, for 5-7 days every 2 weeks." | ( Baum, ES; Gaynon, PS, 1983) |
| "A study of children in relapse with acute nonlymphocytic leukemia (ANLL) previously maintained in remission with combination chemotherapy including cytosine arabinoside (Ara-C) was undertaken by Children's Cancer Study Group (CCSG) to assess the efficacy of cyclocytidine (Cyclo-C), a depot Ara-C, compared to parenteral Ara-C given every 12 hr." | ( Baehner, R; Chard, R; Hammond, D; Higgins, G; Movassaghi, N; Pyesmany, A; Sather, H, 1984) |
| "In a patient with acute myelogenous leukemia (AML) who received 12 courses of MGBG therapy, highly infiltrated lymph node tissue was found to contain the highest concentration of MGBG." | ( Loo, TL; Luna, M; Rosenblum, MG; Stewart, DJ, 1981) |
| "Eleven consecutive patients with acute myelocytic leukemia occurring as a second malignancy were treated with high-dose, timed, sequential chemotherapy." | ( Burke, PJ; Karp, JE; Vaughan, WP, 1983) |
| "Two young patients with secondary acute myeloid leukemia were treated with allogeneic bone marrow transplantation as first-line treatment for their disease." | ( Tricot, G; Van Hoof, A; Verwilghen, RL; Zachee, P, 1984) |
| "Three sequential trials of treatment for acute myelogenous leukemia (AML) involving 173 patients were analyzed to identify clinical and myeloblast-cell progenitor properties in culture related to outcome." | ( Curtis, JE; Elhakim, TM; Hasselback, R; McCulloch, EA; Messner, HA, 1984) |
| "A patient with refractory acute myelogenous leukemia was treated with high-dose cytosine arabinoside (3." | ( Hansen, RM; Heuer, DK; Ritch, PS, 1983) |
| "Twenty-two patients with newly diagnosed acute myelocytic leukemia (AML) and white cell counts (WBC) greater than 100,000/microliters received one, two, or three leukaphereses prior to induction chemotherapy with cytosine arabinoside (Ara-C) and daunorubicin (DNR)." | ( Ambinder, E; Button, G; Cuttner, J; Holland, JF; Meyer, RJ; Norton, L, 1983) |
| "We report a case of ANLL secondary to therapy with melphalan, which was utilized on an adjuvant basis for breast cancer." | ( Crinò, L; Donti, E; Gori, S; Mecucci, C; Tonato, M; Venti, G, 1983) |
| "Two out of three patients with acute myeloid leukemia responded to treatment with small subcutaneous doses of cytosine-arabinoside alone." | ( Andrey, C; Beris, P; Chapuis, B; de Loes, S; Maurice, P; Plancherel, C, 1983) |
| "In cases of acute myeloblastic leukemia in elderly patients where other intensive treatments are contraindicated, it appears to be useful to employ a method of small dose of Ara-C therapy." | ( Emi, N; Kawashima, K; Ohoshima, K; Satake, T; Sugihara, T; Takeyama, H; Yano, K, 1983) |
| "A patient is described with acute myelocytic leukemia refractory to conventional therapy, who also became highly resistant to methotrexate (MTX) after repeated courses of this drug." | ( Bertino, JR; Carman, MD; Duffy, T; Portlock, CS; Rivest, RS; Schornagel, JH; Srimatkandada, S, 1984) |
| "27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA." | ( Boccia, R; Champlin, RE; Gale, RP; Kim, CC; Zighelboim, J, 1984) |
| "A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO." | ( Ankerst, J; Fäldt, R; Flodgren, P; Nilsson, PG; Sjögren, HO, 1984) |
| "Sixteen of 20 patients(80%) with adult ANLL treated with B H-AC X AMP therapy attained complete remission (CR)." | ( Ishige, K; Oguro, M; Takagi, T, 1984) |
| "The experience with acute myelogenous leukemia treated with newer chemotherapeutic agents during pregnancy is limited." | ( Cantini, E; Yanes, B, 1984) |
| "Leukemia cells from patients with acute myeloid leukemia in relapse were treated with various inducers of differentiation of human myeloid leukemia cell lines." | ( Fujita, Y; Honma, Y; Hozumi, M; Kasukabe, T; Nomura, H; Sakurai, M; Sampi, K; Tsushima, S, 1984) |
| "A patient with acute myelogenous leukemia who had normal liver function was treated with amphotericin B for fungal pneumonia." | ( Miller, MA, 1984) |
| "We evaluated the occurrence of acute nonlymphocytic leukemia (ANL) among 1399 women with ovarian cancer who were treated in five randomized clinical trials." | ( Blessing, JA; Boice, JD; Dembo, AJ; Greene, MH; Greer, BE, 1982) |
| "Forty-eight patients with acute myeloblastic leukemia in remission were treated with immunotherapy in addition to remission-maintenance chemotherapy." | ( Baker, MA; Carter, WH; Taub, RN, 1982) |
| "In four male subjects with acute myeloid leukemia treated by intermittent chemotherapy not containing any alkylating agents, FSH, LH, and T levels were normal." | ( Chan, TK; Ng, RP; Todd, D; Wang, C, 1980) |
| "Newer chemotherapy regimens for acute nonlymphocytic leukemia have been effective in many older patients." | ( Walsh, JR, 1981) |
| "Leukemic cells from patients with acute myeloid leukemia underwent morphological, functional, and histochemical changes within 24-48 hr after treatment with 1." | ( Abrahm, J; Cooper, RA; Lange, B; Levis, A; Meo, P; Pegoraro, L; Rovera, G, 1980) |
| "The results of treatment of acute myeloblastic leukemia in patients over 60 years of age are evaluated in a retrospective study of 29 previously untreated patients." | ( Broustet, A; Raynal, F; Reiffers, J, 1980) |
| "Four patients who developed acute myeloblastic leukemia during the treatment of a non-Hodgkin's lymphoma are described." | ( Dumont, J; Mazabraud, A; Natali, JC; Thiery, JP; Trapet, P; Vilcoq, JR, 1980) |
| "One-hundred and seven patients with acute myelogenous leukemia (AML) ranging in age from 15 to 82 yr who were previously untreated, received a 70 day high-dose remission induction regimen consisting of daunorubicin, cytarabine, and thioguanine (TAD)." | ( Foon, KA; Gale, RP; Yale, C; Zighelboim, J, 1981) |
| "Thirty-seven patients with acute myelocytic leukemia were treated with a timed-sequential regimen of arabinosyl cytosine and daunorubicin followed by no further therapy until relapse." | ( Burke, PJ; Karp, JE; Vaughan, WP, 1980) |
| "LBN rats bearing acute myelocytic leukemia (AML) were treated with 100 mg Ara-C/kg q." | ( Burke, PJ; Karp, JE; Vaughan, WP, 1981) |
| "Three patients with acute myelocytic leukemia in remission received high-dose ara-C as consolidation therapy following previous courses of intensive, multiagent consolidation chemotherapy." | ( Early, AP; Preisler, HD; Rustum, YM; Slocum, H, 1982) |
| "Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR) and cytosine arabinoside (ara-C)." | ( Adachi, T; Hamasaki, K; Hara, M; Kimura, I; Kitajima, K; Kohi, F; Lai, M; Sanada, H; Takahashi, I; Takaoka, K; Tokioka, M; Uchida, K; Watanabe, S; Yorimitsu, S, 1982) |
| "The treatment of acute myelocytic leukemia in childhood and young adults has lagged behind that for acute lymphocytic leukemia." | ( Brecher, M; Browman, G; Early, AP; Freeman, A; Preisler, HD; Raza, A; Walker, IR, 1982) |
| "Four cases of acute myelogenous leukemia and six cases of chronic myelogenous leukemia after treatment with azathioprine and prednisone for renal allotransplantation have been described in the literature." | ( Binswanger, U; Briner, J; Fehr, J; Frei, D; Largiadèr, F; Sauter, C, 1980) |
| "Immunotherapy trials for acute myelogenous leukemia mainly have involved adults." | ( Mahoney, DH; Starling, KA, 1981) |
| "Twenty-seven patients with acute myelogenous leukemia (AML) were given remission induction treatment with mitoxantrone, etoposide and cytosine arabinoside (ara-C)." | ( Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U, 1995) |
| "We report a case of acute myelogenous leukemia (AML), which developed from severe aplastic anemia (SAA) and was successfully treated by low-dose Ara-C and aclarubicin with concomitant use of G-CSF (CAG therapy)." | ( Aoyagi, M; Enokihara, H; Koike, T; Nakamura, Y; Saito, K; Tsunogake, S; Watanabe, K; Yamada, K; Yamato, H; Yoshida, M, 1995) |
| "Fifteen patients (8 acute myelogenous leukemia, AML; 4 acute lymphoblastic leukemia, ALL; 3 non-Hodgkin's lymphoma, NHL) were treated with high-dose chemotherapy followed by transplantation with marrow purged with mafosfamide." | ( Almici, C; Carlo-Stella, C; Cottafavi, L; Garau, D; Manoni, L; Rizzoli, V, 1995) |
| "In patients with acute myeloid leukemia, a 41 kDa glycoprotein appears in the urine during remission induction chemotherapy." | ( Dengler, R; Emmerich, B; Lottspeich, F; Mast, AE; Oberthür, W, 1995) |
| "Ara-C is currently used in the treatment of adult acute myeloid leukemia (AML)." | ( Belloc, F; Bernard, P; Boisseau, MR; Cony-Makhoul, P; Dumain, P; Lacombe, F; Puntous, M; Reiffers, J, 1995) |
| "The majority of patients with acute myeloid leukemia (AML) are elderly, and their response to chemotherapy is poorer than that of younger patients." | ( Amess, JA; Davis, CL; Gupta, RK; Leahy, M; Lim, J; Love, S; MacCallum, PK; Oza, AM; Rohatiner, AZ; Whelan, JS, 1995) |
| "A 51-year-old man diagnosed with acute myelogenous leukemia was treated with standard induction chemotherapy." | ( Anderson, RP; Clark, DA, 1995) |
| "Results of chemotherapy in acute myeloid leukemia (AML) have improved slowly or not at all in the last decade." | ( Bleiberg, I; Fabian, I; Kashman, Y; Lishner, M; Rudi, A; Shur, I, 1995) |
| "Two patients with acute nonlymphocytic leukemia (ANLL) who developed neutropenia, bilateral lung infiltrates, and did not respond to conventional antibiotic therapy nor amphotericin B are described." | ( Landau, Z; Resnitzky, P; Rezvak, A; Shtalrid, M, 1995) |
| "Seventy-three children with acute nonlymphocytic leukemia (ANLL) have been treated with ANLL-85 and ANLL-88 protocol at Kyushu-Yamaguchi Children's Cancer Study Group between June, 1985 and February, 1993." | ( Eguchi, H; Ikuno, Y; Inada, H; Ishii, E; Koga, H; Matuzaki, A; Miyazaki, S; Nibu, K; Okamura, J; Ueda, K, 1995) |
| "Fifty patients with previously untreated acute myeloid leukemia were treated with an induction regimen consisting of cytosine arabinoside 100 mg/m2 per day by 18 h i." | ( Chan, CH; Chan, J; Chan, LC; Chan, TK; Chiu, E; Chu, YC; Kwong, YL; Liang, R; Lie, A; Yeung, YM, 1995) |
| "LDC is valuable in the treatment of ANLL in the elderly." | ( Jensen, MK; Pedersen, G; Pedersen, JO; Stentoft, J, 1994) |
| "A patient with acute myelocytic leukemia diagnosed at the 23rd week of gestation received combination chemotherapy, and carried the pregnancy to successful delivery at the 34th week." | ( Imai, A; Kawabata, I; Morishita, S; Tamaya, T, 1994) |
| "The majority of children with acute myeloid leukemia (AML) who are treated exclusively with chemotherapy die of progressive disease." | ( Blakley, RL; Crom, WR; Hurwitz, CA; Krance, RA; Luo, X; Mahmoud, H; Ribeiro, R; Roberts, WM; Santana, VM, 1994) |
| "Patients with acute nonlymphocytic leukemia (ANLL) were treated by continuous infusion of ara-C (100 mg/m2/d x 10 days)." | ( Barra, Y; Carcassonne, Y; Iliadis, A; Ressayre, C; Riva-Lavieille, C, 1994) |
| "We describe a case with acute myelogenous leukemia (AML; M2) who developed prolonged marrow hypoplasia with residual leukemic blasts and recurrent infections after induction chemotherapy." | ( Hahn, JS; Kim, SE; Ko, YW; Lee, SJ; Lee, ST; Min, YH, 1994) |
| "The proliferative characteristics of acute nonlymphoblastic leukemia (ANLL) were studied in vivo, and data were correlated with response to chemotherapy and survival." | ( Danova, M; Giordano, M; Gobbi, P; Mazzini, G; Riccardi, A, 1993) |
| "Sixty-five patients with untreated ANLL and 15 patients with solid tumors and normal bone marrow (BM) received 250 mg/m2 of bromodeoxyuridine (BUdR); bivariate flow cytometric (FCM) analysis then was used to measure cell BUdR incorporation and DNA content to obtain a complete set of kinetic parameters (i." | ( Danova, M; Giordano, M; Gobbi, P; Mazzini, G; Riccardi, A, 1993) |
| "We treated a patient with acute myelogenous leukemia (AML) in a state of second resistant relapse, with high-dose chemoradiotherapy combined with rhGM-CSF (total body irradiation: TBI 3Gy x 4, on days -8 & -7; cytosine arabinoside: Ara-C 3g/m2, iv, q12h, on days -5-2; rhGM-CSF 250 micrograms/m2/day, cont." | ( Aoki, Y; Inoue, T; Irie, S; Kikuno, K; Okamoto, S; Shimane, M; Takada, M; Takahashi, S; Tanosaki, R; Tojo, A, 1993) |
| "Ten patients with acute myeloblastic leukemia (AML) in first relapse were treated with high-dose cytosine-arabinoside (ara-C, 3 g/m2/12 hours x 4) and amsacrine (150 mg/m2/day x 5)." | ( Belloc, F; Bernard, P; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Laurent, G; Marit, G; Puntous, M; Reiffers, J, 1993) |
| "In 102 consecutive patients with MDS or acute myelogenous leukemia (AML) following MDS, pre-treatment variables were studied in relation to the response to treatment with low-dose ara-C." | ( Forsblom, AM; Gahrton, G; Hellström-Lindberg, E; Kock, Y; Lindberg, G; Ost, A; Robèrt, KH, 1994) |
| "Thirty-two consecutive, unselected acute myeloid leukemia (AML) patients (pts) of all FAB-subtypes with a median age of 68 years were treated with intensive induction chemotherapy consisting of one or two cycles of daunorubicin 30 mg/m2 day 1-3 and Ara C 100 mg/m2 as continuous infusion day 1-7." | ( Jehn, U, 1994) |
| "In the past decade, therapy-related acute myeloid leukemia (t-AML) following treatment with regimens that include inhibitors of topoisomerase-II (TOPO-II) has been reported with increasing frequency." | ( Rubinstein, L; Smith, MA; Ungerleider, RS, 1994) |
| "The early occurrence of five cases of acute myeloid leukemia (AML) in children treated for primary rhabdomyosarcoma on the Intergroup Rhabdomyosarcoma Study III (IRS III) has prompted this report." | ( Donaldson, SS; Ensign, LG; Heyn, R; Khan, F; Maurer, HM; Ruymann, F; Smith, MA; Vietti, T, 1994) |
| "A young patient with acute myelogenous leukemia was treated with high-dose cytarabine (3." | ( Friedland, S; Loya, N; Shapiro, A, 1993) |
| "Therapy-related acute myeloid leukemia (t-AML), often presenting as myelodysplasia (t-MDS), has become the most serious long-term complication of cancer therapy and offers a unique opportunity to study chemical leukemogenesis." | ( Andersson, M; Daugaard, G; Ersbøll, J; Hansen, SW; Hou-Jensen, K; Larsen, SO; Nielsen, D; Pedersen-Bjergaard, J; Philip, P; Sigsgaard, TC, 1993) |
| "In a phase I study, 68 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and accelerated- and blastic-phase CML received induction therapy consisting of cytarabine 3 g/m2 by infusion over 3 hours daily for 5 days, with escalating doses of mitoxantrone 40 to 80 mg/m2 over 1 to 2 days by intravenous infusion over 15 minutes." | ( Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993) |
| "Current intensive chemotherapy for acute nonlymphoblastic leukemia (ANLL) results in a complete remission in the majority of patients." | ( Amylon, MD; Blume, KG; Chao, NJ; Forman, SJ; Long, GD; Negrin, RS; Stein, AS; Wong, RM, 1993) |
| "A 47-year-old woman with acute myeloblastic leukemia developed disseminated papules and pustules after chemotherapy." | ( Aractingi, S; Baurmann, H; Caux, F; Dombret, H; Dubertret, L; Reygagne, P; Romand, S, 1993) |
| "The second patient had acute myelogenous leukemia and experienced knee arthritis after chemotherapy, and the third suffered oligoarthritis after a second heart transplantation." | ( Andréu, JL; Barbadillo, C; Cuende, E; E-Mazzucchelli, R; Isasi, C; Trujillo, A, 1993) |
| "Following irradiation alone, secondary acute nonlymphocytic leukemia (ANLL) is uncommon; following chemotherapy alone, the risk is increased, but not as much as when combined modality treatments are used." | ( Brusamolino, E; Fiacchini, M; Gobbi, PG; Tura, S; Zinzani, PL, 1993) |
| "The risk of ANLL was assessed in 503 patients with Hodgkin's disease (HD) homogeneously treated with combined modality therapy (mechlorethamine, vincristine, procarbazine, and prednisone [MOPP] plus radiotherapy)." | ( Brusamolino, E; Fiacchini, M; Gobbi, PG; Tura, S; Zinzani, PL, 1993) |
| "In relapsed and refractory adult acute myeloid leukemia, higher than conventional doses undoubtedly enhance the efficacy of Ara-C salvage therapy." | ( Archimbaud, E; Thomas, X, 1995) |
| "A case of acute nonlymphocytic leukemia (ANLL) occurring 2 years after the diagnosis of multiple myeloma (MM) that had been treated by only one course of melphalan/prednisone chemotherapy is reported." | ( Hossfeld, DK; Junge, I; Seeger, D; Weh, HJ, 1996) |
| "The standard treatment of patients with acute myeloid leukemia (AML) has depended on the elimination of the leukemic clone with cytotoxic myeloablation." | ( Tallman, MS, 1996) |
| "Patients with newly diagnosed acute myelogenous leukemia (AML) with persistent leukemia after their first course (CO1) of induction chemotherapy are generally given a second similar course, although their outcome is known to be worse than CO1 responders even when a complete remission (CR) is achieved." | ( Anderlini, P; Estey, EH; Freireich, EJ; Ghaddar, HM; Kantarjian, HM; Keating, MJ; O'Brien, S; Pierce, S; Smith, TL, 1996) |
| "A 50-year-old male with acute myelocytic leukemia (AML) achieved complete remission after combination chemotherapy." | ( Imanaka, F; Kouzai, K; Okuhara, T; Takimoto, Y, 1996) |
| "We encountered a 71-year-old female with acute myelogenous leukemia (AML, M1), who maintained a steady hematological state for 22 months under ubenimex monotherapy." | ( Ito, S; Miyairi, Y; Murai, K; Narigasawa, Y; Numaoka, H; Oikawa, H; Ono, Y; Shimosegawa, K; Sugawara, T; Utsugisawa, T, 1995) |
| "Those patients with ANLL were nursed in a single room; patients with ALL were nursed in a single room during remission induction therapy only." | ( Dankert, J; Kamps, WA; Muis, N, 1996) |
| "Twenty-one patients with acute myeloid leukemia (AML) who failed to enter complete remission (CR) after first-line standard-dose remission-induction therapy with 7 days of cytarabine and 3 days of daunorubicin were treated with a salvage regimen containing intermediate-dose cytosine arabinoside (Ara-C) 2 x 500 mg/m2/day during 7 days in combination with continuous infusions of idarubicin 12 mg/m2/day on days 1, 3, and 5." | ( Dardenne, M; De Witte, T; Hayat, M; Kurstjens, R; Labar, B; Muus, P; Ribeiro, M; Roozendaal, K; Selleslag, D; Solbu, G; Suciu, S; Zittoun, R, 1996) |
| "A 39-year-old male with acute myelogenous leukemia and concomitant porphyria cutanea tarda was admitted to the hospital for consolidation chemotherapy of his leukemia." | ( Arnold, KE; Funke, G; Nolte, FS; Sweat, H; Winton, EF, 1996) |
| "Three cases of secondary acute myeloid leukemia (AML) that developed after long term treatment with oral etoposide were reported." | ( Ashihara, E; Fujita, N; Goto, H; Hatta, T; Hirai, H; Inaba, T; Kikuta, T; Nakagawa, M; Shimazaki, C; Sudo, Y; Sumikuma, T; Yamagata, N, 1996) |
| "We report a case of 53-year-old man with acute myelogenous leukemia (M2) showing a karyotype of t(7;11) (p15;p15), del(10) (q11;q12), who was complicated with perforation of a duodenal ulcer during the antileukemic chemotherapy using behenoyl ara-C, daunorubicin, 6-mercaptopurine and prednisolone." | ( Enomoto, S; Ishida, Y; Ito, S; Ito, T; Kaneko, J; Kuriya, S; Miyairi, Y; Murai, K; Narigasawa, Y; Numaoka, H; Ono, Y; Shimosegawa, K; Sugawara, T; Utsugisawa, T, 1997) |
| "These findings suggest that the ANLL-9205 protocol is an effective and safe treatment regimen for childhood AML." | ( Fujimoto, T; Gushiken, T; Horikoshi, Y; Ishida, Y; Kawakami, K; Kawamura, N; Kikuta, A; Koizumi, S; Maeda, H; Mimaya, J; Mugishima, H; Ohta, S; Oka, T; Okada, N; Sekine, I; Shimizu, H; Utsumi, J; Watanabe, A; Yamamura, Y, 1997) |
| "Treatment-related acute myeloid leukemia (t-AML) following successful therapy of a primary malignancy has been recognized with increasing frequency among cancer survivors over the past several years." | ( Aplan, PD; Chervinsky, DS; Stanulla, M; Wang, J, 1997) |
| "A case of acute myelocytic leukemia of the FAB-M2 subtype in a patient who experienced pigmentary nail changes in conjunction with idarubicin therapy is presented." | ( Borecky, DJ; Keeling, JH; Stephenson, JJ; Vukelja, SJ, 1997) |
| "A 47-year-old man with acute myeloblastic leukemia (AML) developed angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) 4 months after induction chemotherapy for AML." | ( Daibata, M; Ido, E; Kubonishi, I; Kuzume, T; Miyoshi, I; Murakami, K; Taguchi, H, 1997) |
| "In the ANLL 9205 protocol, anthracycline was used with a continuous infusion of cytosine arabinoside, followed by an intensive sequential post remission chemotherapy of short duration, 42/46 patients (91." | ( Fujimoto, T; Hirota, T; Horikoshi, Y; Kamitamari, A; Katano, N; Kawamura, N; Mimaya, J; Tsuji, Y; Tsurusawa, M; Yanai, M, 1997) |
| "Treatment failure of patients with acute myelogenous leukemia (AML) is frequently due to the development of multidrug resistance phenotype blasts." | ( Burbage, C; Frankel, AE; Fu, T; Hall, P; Harris, B; Tagge, EP; Willingham, MC, 1997) |
| "Herein we describe two patients with acute nonlymphoblastic leukemia in whom cutaneous small vessel necrotizing vasculitis developed after high-dose single-agent chemotherapy with ara-C." | ( Ahmed, I; Chen, KR; Gibson, LE; Nakayama, H, 1998) |
| "32 patients of denovo-ANLL were treated with Doxorubicin, Ara-C and 6-Mercaptopurine (DAM) regimen." | ( Barua, A; Rahman, J; Rashid, MA; Sayeed, MA; Yunus, AB, 1997) |
| "We report a high risk of therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) in patients receiving oral administration of etoposide for recurrent breast cancer." | ( Adachi, M; Horiike, S; Huang, CL; Ieki, Y; Konaka, Y; Miyake, M; Onishi, R; Taki, T; Yagita, M, 1998) |
| "Treatment of acute myelogenous leukemia is challenging in the setting of ischemic heart disease because anthracycline and anthracenedione drugs used in induction chemotherapy may potentiate myocardial dysfunction." | ( DiSalle, M; Lifton, R; Woodlock, TJ, 1998) |
| "OCI/AML-2 acute myeloid leukemia cells were found to undergo apoptosis after treatment with y rays from a 137Cs source." | ( Bump, EA; Hedley, DW; Sheng-Tanner, X, 1998) |
| "Twelve consecutive patients with acute myelogenous leukemia (AML) or refractory anemia with excess of blasts in transformation (RAEB-t) who were not tolerable for standard-dose chemotherapy were treated with CAG regimen (low-dose cytosine arabinoside [Ara-C] plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor [G-CSF])." | ( Abe, T; Bai, A; Hasegawa, Y; Hori, M; Kojima, H; Komeno, T; Nagasawa, T; Nara, N; Ninomiya, H, 1999) |
| "Patients with acute myelogenous leukemia secondary to an antecedent hematologic disturbance or cytotoxic chemotherapy are considered to have a very low likelihood of leukemia-free survival regardless of the form of post-remission therapy." | ( Khoubian, F; Lee, M; Paquette, R; Sawyers, C; Schiller, G; Territo, M, 1999) |
| "An 11-year-old Hispanic boy with acute myeloblastic leukemia developed symptoms of pseudotumor cerebri (headache, diplopia, photophobia, nausea, vomiting) after receiving chemotherapy including cytarabine." | ( Fort, JA; Smith, LD, 1999) |
| "She had given a diagnosis of acute myelogenous leukemia (FAB classification M1) a year ago and treated with 3 cycles of cytarabine and anthracycline or etoposide for 4 months, achieving complete remission state." | ( Harada, N; Shibuya, T; Taniguchi, S; Uchida, N, 1999) |
| "Six patients developed therapy-related acute myelogenous leukemia (t-AML)." | ( Behnisch, W; Göbel, U; Hilgenfeld, E; Schneider, DT; Schwabe, D; Wessalowski, R; Zoubek, A, 1999) |
| "The patient was diagnosed with acute myelogenous leukemia and treated with induction chemotherapy." | ( Hinrichs, SH; Iwen, PC; Lackner, RP; McCarthy, DI; Rinaldi, MG; Sigler, L; Sutton, DA; Tarantolo, S, 2000) |
| "Several prospective randomized trials in acute myelocytic leukemia (AML) documented a lower relapse rate with autologous bone marrow transplantation (ABMT) than with conventional chemotherapy." | ( Bauters, F; Bellal, N; Douay, L; Fouillard, L; Gorin, NC; Isnard, F; Jouet, JP; Labopin, M; Laporte, JP; Lesage, S; Lopez, M; Najman, A; Perot, C; Van Den Akker, J, 1999) |
| "A report of two patients in whom acute myelogenous leukemia (AML) developed after treatment with strontium-89 and a review of the literature are presented." | ( Kossman, SE; Weiss, MA, 2000) |
| "BFM-83 induction therapy for ANLL (ARA-C + RUB + VP-16) which is applied to children with acute non-lymphoblastic leukemia (ANLL) commonly contributes to severe adverse reactions." | ( Bodalski, J; Bolanowski, W; Nowak, K; Stolarska, M; Zalewska-Szewczyk, B, 1998) |
| "We report an adult male patient with acute myeloid leukemia who developed CSP-induced encephalopathy under treatment for allogeneic BMT from an unrelated donor." | ( Chao, TY; Chen, CY; Chen, YC; Ho, CL, 2000) |
| "We report a patient suffering from acute nonlymphocytic leukemia (ANLL) 3 years after treatment for stage IV ovarian cancer began." | ( Fujii, S; Fukushi, Y; Futagami, M; Higuchi, T; Saito, Y; Sakamoto, T; Sato, S; Takami, H; Yokoyama, Y, 2000) |
| "We treated 153 patients with de novo acute myeloid leukemia (AML) with two induction courses of conventional-dose cytosine arabinoside (ara-C) and idarubicin (AIDA) followed by either a third course of AIDA, high-dose ara-C or bone-marrow transplantation." | ( Beelen, DW; Brittinger, G; Flasshove, M; Kemmeries, G; Meusers, P; Noppeney, R; Roggenbuck, U; Scheulen, ME; Schütte, J; Seeber, S; Sohrab, S, 2000) |
| "Remission induction chemotherapy for acute myelogenous leukemia typically combines cytarabine with an anthracycline or anthracycline derivative." | ( Andresen, S; Elson, P; Hussein, M; Kalaycio, M; Lichtin, A; Pohlman, B; Tripp, B, 2001) |
| "The treatment of acute myelogenous leukemia (AML) in children, has been hampered by few new effective agents developed in the past 30 years." | ( Bell, BA; Chang, MN; Weinstein, HJ, 2001) |
| "Treatment of acute myeloid leukemia (AML) involves aggressive myelosuppressive chemotherapy that is generally administered on an inpatient basis." | ( Allan, DS; Buckstein, R; Imrie, KR, 2001) |
| "Elderly patients with acute myeloid leukemia (AML) have an unfavourable prognoses due to low remission rates, short remission durations, and a high treatment related toxicity." | ( Gotto, H; Hartmann, F; Jacobs, G; Pfreundschuh, M; Schwamborn, J, 2001) |
| "All 35 patients were treated with the ANLL91 protocol consisting of etoposide, high-dose cytarabine, and anthracyclines." | ( Eguchi, M; Hayashi, Y; Hibi, S; Hongo, T; Imaizumi, M; Ishii, E; Isoyama, K; Kamada, N; Kawasaki, H; Kinukawa, N; Kosaka, Y; Mizutani, S; Nishimura, S; Oda, M; Oda, T; Okamura, T; Okawa, H; Tsukimoto, I, 2001) |
| "126 inpatients diagnosed as acute myeloid leukemia between January 1993 to December 1997 were treated with mitoxantrone with other chemical agents." | ( Chen, Y; Du, X; Fu, J; Lu, D; Qiu, J; Wang, D, 1999) |
| "A 41-year-old woman with relapsed acute myelogenous leukemia was treated twice with idarubicin hydrochloride and cytarabine." | ( Iwato, K; Kyo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suetsugu, Y; Sugihara, T; Wada, H; Yamada, O; Yata, K; Yawata, Y, 2002) |
| "A 52-year-old woman with acute myeloid leukemia developed invasive pulmonary aspergillosis during remission induction chemotherapy." | ( Miyanishi, E; Nakase, K; Shiku, H; Tamaki, S; Tanigawa, M; Tsuji, K; Yazaki, A, 2002) |
| "Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the juxtamembrane domain of the FLT3 receptor, suggesting that it may be a target for kinase inhibitor therapy." | ( Abe, K; Amaral, SM; Apatira, M; Boulton, CL; Curley, DP; Duclos, N; Giese, NA; Gilliland, DG; Hollenbach, S; Kelly, LM; Li, J; Lokker, NA; Neuberg, D; Pandey, A; Scarborough, RM; Sullivan, CM; Williams, I; Yu, JC, 2002) |
| "We describe a 12-year-old boy with acute myeloid leukemia who developed pleuropericarditis while he was neutropenic and was receiving intravenously administered antibiotic and antifungal therapy for pneumonia." | ( Bearman, G; Brown, AE; Heath, JA; Kiehn, TE; LaQuaglia, MP; Steinherz, LJ; Steinherz, PG; Wong, M, 2002) |
| "Despite improvements in the treatment of acute myeloid leukemia (AML), approximately 50% of children die of the disease." | ( Lockwood, L; Marshall, GM; O'Brien, TA; Oswald, CM; Rice, M; Russell, SJ; Shaw, PJ; Teague, L; Tiedemann, K; Vowels, MR, 2002) |
| "Ten patients with acute myelogenous leukemia or high risk myelodysplastic syndrome who had achieved complete remission following treatment with the CAG regimen were monitored for peripheral blood WT1 expression mRNA levels." | ( Arai, H; Arai, Y; Gunji, H; Handa, T; Maki, K; Mitani, K; Nakamura, F; Nakamura, Y; Saito, K; Tadokoro, J, 2002) |
| "We report a case of acute myeloid leukemia with no preceding myelodysplastic syndrome, occurring after 2 years of hydroxyurea therapy in a patient with sickle cell disease." | ( Al-Dabbous, IA; Al-Jam'a, AH; Al-Khatti, AA; Esan, FG, 2002) |
| "We report a case of secondary acute myelogenous leukemia (AML) with 11q23 cytogenetic abnormality and mixed lymphoid leukemia (MLL) gene expression in a patient treated with Y90 labeled anti-CD20 antibody (Zevalin)." | ( Dewald, G; Gordon, LI; Kent, SA; Multani, P; Nabhan, C; Peterson, LA; Tallman, MS, 2002) |
| "The authors describe two children with acute myelogenous leukemia (AML) with extensive invasive aspergillosis who were successfully treated both for their infection and the underlying malignancy." | ( Choi, SS; Dinndorf, PA; Seibel, NL; Singer, MS; Vezina, G, 2003) |
| "16-yr-old boy with acute myeloid leukemia was effectively treated with hemodialysis for prerenal and renal ARF mediated by vasomotor, infectious and toxic factors." | ( Jarmoliński, T; Nowakowska, J; Peregud-Pogorzelski, J; Zimoń, T, 2002) |
| "Therapy results in childhood acute myelogenous leukemia (AML) differ from those of acute lymphoblastic leukemia (ALL)." | ( Debski, R; Juraszewska, E; Malinowska, I; Mazur, B; Ploszynska, A; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wysocki, M, 2002) |
| "A 62-year-old man diagnosed with acute myelogenous leukemia which had developed from myelodysplastic syndrome received cytarabine and idarubicine as an induction therapy." | ( Ashihara, E; Fuchida, S; Fujita, N; Inaba, T; Nakagawa, M; Ochiai, N; Okano, A; Shimazaki, C; Uchida, R, 2003) |
| "When a 41-year-old woman with acute myeloblastic leukemia in relapse was treated using the big ICE protocol, because of lack of efficacy of other chemotherapy regimens." | ( Beyan, C; Cetin, T; Kaptan, K; Nevruz, O, 2002) |
| "The treatment of acute myeloid leukemia (AML) permits in a population of 25 to 60 years, a complete remission (CR) about 60 to 85% with relapse free survival at 5 years from 45 to 60%." | ( Benchekroun, S; Harif, M; Qachouh, M; Quessar, A, 2003) |
| "Results of treatment of childhood ANLL remained unsatisfactory for a long time, and introduction of a new drug seemed justified as the EFS achieved in this disease between 1993-97 was 42%." | ( Balcerska, A; Balwierz, W; Chybicka, A; Dobaczewski, G; Dłuzniewska, A; Kowalczyk, J; Krenke, K; Lewandowska, D; Malinowska, I; Matysiak, M; Mikołajczyk, M; Niedźwiedzki, M; Rokicka-Milewska, R; Sońta-Jakimczyk, D; Stefaniak, J; Styczyński, J; Tomaszewska, R; Wachowiak, J; Wysocki, M, 2003) |
| "We encountered a patient with acute myeloid leukemia who developed depressive disorder induced by steroid given for graft-versus-host disease treatment." | ( Fujisawa, S; Ito, M; Kanamori, H; Onishi, H; Onose, M; Yamada, T, 2003) |
| "A-36-year-old male diagnosed with acute myelogenous leukemia (AML, M2) failed to achieve a complete remission after having undergone two courses of induction chemotherapy (idarubicin hydrochloride + cytarabine, high-dose cytarabine), and moreover, his cerebrospinal fluid (CSF) then revealed abnormal blasts." | ( Doki, N; Hatsumi, N; Irisawa, H; Miyawaki, S; Saito, Y; Sakura, T, 2003) |
| "We describe a patient with acute myelogenous leukemia (AML) who was complicated with severe tumor lysis syndrome (TLS) after a single day of chemotherapy; a previously unreported occurrence." | ( Fujii, S; Kikuchi, T; Miyata, A, 2003) |
| "In patients with acute myeloid leukemia requiring parenteral nutrition, glycyl-glutamine supplementation could hasten neutrophil recovery after intensive myelosuppressive chemotherapy." | ( Diehl, V; Fuchs, M; Heck, G; Hermann, K; Herrmann, HJ; Holsing, A; Kremer, G; Scheid, C; Schwenk, A; Söhngen, D; Waldschmidt, D, 2004) |
| "We treated 305 de novo acute myeloid leukemia (AML) patients aged | ( Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G, 2004) |
| "We report a case of acute myeloblastic leukemia diagnosed during the third trimester of gestation and treated with chemotherapeutic agents before delivery." | ( Akercan, F; Cagirgan, S; Donmez, A; Mgoyi, L; Ozkinay, E; Vural, F; Yucebilgin, MS, 2004) |
| "Interactions between acute myelogenous leukemia (AML) blasts and non-leukemic cells in the bone marrow seem to be important for both disease development and susceptibility to chemotherapy." | ( Bruserud, Ø; Gjertsen, BT; Glenjen, NI; Ryningen, A; Wergeland, L, 2004) |
| "Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy." | ( Clark, J; Cohen, P; DeAngelo, DJ; Estey, E; Fox, EA; Galinsky, I; Gilliland, DG; Grandin, W; Griffin, JD; Klimek, V; Lebwohl, D; Neuberg, D; Nimer, SD; Stone, RM; Wang, Y, 2005) |
| "Twenty-eight patients had acute myelogenous leukemia (7 untreated secondary acute myelogenous leukemia, 11 in first relapse, and 10 in second relapse or refractory), 1 patient had refractory/relapsed acute lymphoblastic leukemia, and 2 patients had untreated chronic myelogenous leukemia blast crisis." | ( Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ, 2004) |
| "A 56-year-old woman with acute myeloid leukemia had two rapidly growing necrotizing nodules with ulcer formation on her head after the first course of consolidation therapy." | ( Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M, 2004) |
| "Planning therapy for acute myelogenous leukemia (AML) is difficult because of the heterogeneous nature of the disease and varying patient age at presentation." | ( Beardell, F; Brunner, J; Capizzi, R; Cohn, J; Ferbér, A; Filicko, J; Flomenberg, N; Garcia-Manero, G; Grosso, D; Martinez, J; Mookerjee, B; Rose, L; Tice, D; Wagner, JL, 2004) |
| "Cure rates for patients with acute myeloid leukemia (AML) remain low despite ever-increasing dose intensity of cytotoxic therapy." | ( Corsello, SM; Deangelo, DJ; Golub, TR; Ross, KN; Stegmaier, K; Wong, JS, 2005) |
| "The authors report on a 17-year-old with acute myelogenous leukemia who was admitted to the Pediatric ICU for treatment of septic shock, respiratory failure, myocardial dysfunction, and renal insufficiency." | ( Tobias, JD; Wheeler, AD, 2005) |
| "Twenty-nine patients with acute myeloid leukemia (AML) received a salvage therapy of amsacrine plus IDAC and etoposide, while 22 patients with acute lymphoblastic leukemia (ALL) received amsacrine plus IDAC." | ( Ahn, BM; Baek, JH; Jeon, SB; Kim, DH; Kim, JG; Lee, KB; Moon, JH; Sohn, SK; Sung, WJ, 2005) |
| "The development of such drugs for the treatment of acute myeloid leukemia (AML) is ongoing." | ( Almstedt, M; Claus, R; Lübbert, M, 2005) |
| "The MRC AML (Medical Research Council Acute Myeloid Leukemia) Working Group designed a trial comparing fludarabine and high-dose cytosine (FLA) with standard chemotherapy comprising cytosine arabinoside, daunorubicin, and etoposide (ADE)." | ( Burnett, AK; Craig, JI; Littlewood, T; Milligan, DW; Wheatley, K, 2006) |
| "Standard practice in older patients with acute myeloid leukemia (AML) is induction chemotherapy (ICT) followed by post-remission chemotherapy (PRT)." | ( Abou-Jawde, RM; Advani, A; Kalaycio, M; Pohlman, B; Rybicki, L; Sekeres, M; Sobecks, R, 2006) |
| "cereus in a 37-year-old woman with acute myeloblastic leukemia, who recovered following total parenteral nutrition and treatment with imipenem and vancomycin." | ( Argaud, L; Le Scanff, J; Martin, O; Mohammedi, I; Robert, D; Thiebaut, A, 2006) |
| "A 67-year-old man with acute myeloid leukemia (AML) was treated with low-dose decitabine." | ( Cashen, AF; Devine, H; DiPersio, J, 2006) |
| "The therapeutic approach to acute myeloid leukemia is based on chemotherapy, but the side effects of the drugs used and various complications, including infections and bleedings, are sometimes fatal." | ( Kizaki, M, 2006) |
| "A 79-year-old male with acute myelogenous leukemia developed acute right knee arthritis during admission, after the use of broad-spectrum antibiotics before chemotherapy." | ( Chang, HN; Chen, WS; Chou, CT; Chou, YL; Tsai, CY; Wang, HP; Yen, YF, 2007) |
| "Etoposide-induced treatment-related acute myelogenous leukemia (t-AML) is characterized by rearrangements of the mixed lineage leukemia (MLL) gene with one of its >50 partner genes, most probably as a consequence of etoposide-induced DNA double-strand breaks (DSBs)." | ( Hars, ES; Lin, CP; Liu, LF; Lyu, YL, 2006) |
| "A 51-year-old man with acute myeloblastic leukemia (M4) underwent two courses of remission induction therapy with cytarabine and daunorubicin." | ( Akiyama, H; Honma, M; Ito, T; Muramatsu, T; Negishi, K; Ohashi, K; Sakai, M; Sakamaki, H; Shitara, M; Suzuki, T; Ueki, T; Yamashita, T, 2006) |
| "A 48-yr-old man with acute myeloid leukemia (AML) required urgent allogeneic hematopoietic stem cell transplantation because of failed attempts to induce remission via chemotherapy." | ( Daniel, J; Hari, P; Knox, J; Saeian, K; Surapaneni, SN, 2007) |
| "Acute lymphoblastic and acute myeloid leukemia cells were incubated with standard induction chemotherapy, and individual cell stiffness was tracked with atomic force microscopy." | ( Fletcher, DA; Lam, WA; Rosenbluth, MJ, 2007) |
| "In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival." | ( Angulo-Gonzalez, D; Cornely, OA; Goh, YT; Hardalo, C; Helfgott, D; Holowiecki, J; Maertens, J; Perfect, J; Petrini, M; Stockelberg, D; Suresh, R; Ullmann, AJ; Walsh, TJ; Winston, DJ, 2007) |
| "We identified 2 cases of secondary acute myeloid leukemia (AML) following adult T-cell leukemia/lymphoma (ATL) in patients who had previously received chemotherapy." | ( Hanada, S; Otsuka, M; Owatari, S; Takeshita, T; Uozumi, K, 2007) |
| "For other acute myeloid leukemias (AML), many trials of combination chemotherapy have not improved the outcome of elderly patients." | ( Usui, N, 2007) |
| "Induction therapy for acute myeloid leukemia (AML) usually consists of 7 days of cytarabine at 100-200 mg/m(2)/day and an anthracycline." | ( Appelbaum, FR; Balcerzak, SP; Dakhil, SR; Head, DR; Karnad, AB; Petersdorf, SH; Rankin, C; Terebelo, HR; Willman, CL, 2007) |
| "The major problem in the treatment of acute myeloid leukemia (AML) patients results from multidrug resistance to administered anticancer agents." | ( Avcu, F; Baran, Y; Gündüz, U; Gür, B; Kaya, P; Ural, AU, 2007) |
| "A 47-year-old man with newly diagnosed acute myeloblastic leukemia and non-insulin-dependent diabetes mellitus developed Trichosporon asahii fungemia while receiving caspofungin as empirical antifungal therapy." | ( Aydin, F; Aydin, K; Bayramoglu, G; Sonmez, M; Tosun, I, 2008) |
| "Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory." | ( Dastugue, N; Huguet, F; Ifrah, N; Jourdan, E; Perreau, V; Pigneux, A; Reiffers, J; Salmi, LR; Sotto, JJ; Vey, N, 2007) |
| "Treatment of acute myeloid leukemias (AMLs) with CA4P leads to disruption of mitochondrial membrane potential, release of proapoptotic mitochondrial membrane proteins, and DNA fragmentation, resulting in cell death in part through a caspase-dependent manner." | ( Butler, J; Chaplin, DJ; Feldman, E; Hooper, AT; Karajannis, MA; Petit, I; Rafii, S; Shido, K; Steller, H; Vincent, L; Young, L, 2008) |
| "Fifty-seven patients with acute myelogenous leukemia (AML) received the following treatment in our hospital between May 1992 and April 2005." | ( Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N, 2007) |
| "Data on the impact of age in acute myeloid leukemia (AML) patients <30 years treated in pediatric and adult trials are scarce." | ( Büchner, T; Creutzig, U; Döhner, H; Reinhardt, D; Sauerland, MC; Schlenk, RF; Zimmermann, M, 2008) |
| "Treatment of older patients with acute myeloid leukemia (AML) represents a significant challenge." | ( Burnett, AK; Kell, J, 2007) |
| "Twenty-one acute myeloid leukemia (AML) patients were enrolled and received oral induction therapy with cytarabine ocfosfate (SPAC) and etoposide (EP)." | ( Horikoshi, A; Hosokawa, Y; Sawada, S; Takei, K, 2008) |
| "One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years." | ( Bian, S; Liu, S; Meng, Q; Mi, Y; Wang, J; Xue, Y; Yu, W; Zhao, Y, 2008) |
| "Adults 18-60 years old with acute myelogenous leukemia (AML) should undergo some form of postremission therapy, however, how much and what kinds of postremission chemotherapy remain unclear." | ( Rowe, JM, 2008) |
| "Clinical trials in solid tumors and in acute myeloid leukemia have demonstrated the potential to improve treatment outcome when histamine dihydrochloride is combined with immunotherapy." | ( Ho, AD; Perz, JB, 2008) |
| "Therapy-related acute myeloid leukemia (t-AML) caused by MLL rearrangements (rMLL) can arise from topoisomerase II agents." | ( Bleibel, WK; Bogni, A; Cai, X; Cheng, C; Dolan, ME; Fan, Y; Liu, W; Pei, D; Pui, CH; Relling, MV; Rocha, JC; Yang, J; Yang, W, 2008) |
| "Treatment was not linked to the rate of acute myeloid leukemia in any defined subgroup, including patients with an increase of marrow blasts or an unfavorable karyotype." | ( Cazzola, M; Della Porta, MG; Dybedal, I; Hellström-Lindberg, E; Invernizzi, R; Jädersten, M; Malcovati, L; Montgomery, SM; Pascutto, C; Porwit, A, 2008) |
| "We report a case of acute myeloid leukemia with folliculitis, Sweet's syndrome, and neutrophilic panniculitis after remission induction chemotherapy for acute myeloid leukemia." | ( Ito, T; Nakazawa, H; Saida, T; Uhara, H, 2008) |
| "Standard treatment of acute myeloid leukemia (AML) results in a median survival of approximately 1 year." | ( Estey, E, 2008) |
| "Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity." | ( Abboud, CN; Blum, W; Byrd, JC; Fehniger, TA; Kefauver, C; Marcucci, G; Payton, JE; Vij, R, 2009) |
| "In 269 patients treated for acute myelogenous leukemia-myelodysplastic syndrome (AML-MDS) during 2002-2007, evidence of IA was collected using high-resolution computed tomography and galactomannan measurement in bronchoalveolar lavage fluid specimens." | ( Doorduijn, JK; el Barzouhi, A; Lugtenburg, PJ; Polinder, S; Rijnders, BJ; Slobbe, L; Steyerberg, EW, 2008) |
| "Elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) have a poor prognosis due to low response rates (26-46%) to standard chemotherapy and high treatment-related mortality (11-31%)." | ( Alkan, S; Barton, K; Germano, E; Godwin, J; Michaelis, L; Nand, S; Rychlik, K; Smith, S; Stiff, P; Veerappan, R, 2008) |
| "In elderly patients with acute myeloid leukemia, NPM1 mutations are associated with achievement of complete remission, and the genotype 'mutant NPM1 without FLT3-ITD' appears to be a predictive marker for response to all-trans retinoic acid given as an adjunct to intensive chemotherapy (ClinicalTrials." | ( Anhalt, A; Benner, A; Bullinger, L; Corbacioglu, A; Del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Götze, K; Groner, S; Habdank, M; Hartmann, F; Kayser, S; Kirchen, H; Kneba, M; Koller, E; Krebs, B; Schlenk, RF; Späth, D, 2009) |
| "In a significant proportion of acute myeloid leukemia (AML) cases the canonical WNT pathway is upregulated and targeting the WNT/LEF1 signaling cascade in AML may be a promising approach to develop new treatments for this entity." | ( Gandhirajan, RK; Gehrke, I; Hallek, M; Kreuzer, KA; Minke, KS; Puetter, A; Schlösser, A; Schmitt, EK; Staib, P, 2009) |
| "We report a patient with acute myeloid leukemia who developed HSC during post-remission consolidation chemotherapy and was treated with a prolonged course of caspofungin followed by fluconazole." | ( Chia, HY; Koh, LP; Liu, TC; Poon, LM; Tan, LK, 2009) |
| "Successful treatment of acute myeloid leukemia (AML) remains a therapeutic challenge, with a high percentage of patients suffering from persistent or relapsed disease." | ( Ayres, M; Beck, JF; Chen, ZS; Ehninger, G; Gandhi, V; Grube, M; Guo, Y; Illmer, T; Jedlitschky, G; Köck, K; Kroemer, HK; Kruh, GD; Ritter, CA; Schaich, M; Siegmund, W, 2009) |
| "cereus in a patient with newly diagnosed acute myeloid leukemia (AML) during remission induction therapy." | ( Ishikawa, T; Ishitsuka, K; Katsuya, H; Sasaki, H; Takamatsu, Y; Takata, T; Tamura, K, 2009) |
| "Among cases of therapy-related acute myeloid leukemia (t-AML) due to DNA topoisomerase II inhibitors, 11q23 abnormality is often detected." | ( Irie, T; Mori, A; Morioka, M; Saito, M; Tanaka, M, 2009) |
| "A 64-year-old man with acute myelogenous leukemia (FAB classification, M7) in remission received consolidation chemotherapy with mitoxantrone/cytosine arabinoside." | ( Gondo, H; Kawatani, E; Kishikawa, Y; Kuwahara, N; Matsuishi, E; Mori, D; Osoegawa, K; Sankoda, C, 2009) |
| "Cytarabine (ara-C) is the key agent for treating acute myeloid leukemia (AML)." | ( Iwasaki, H; Kishi, S; Negoro, E; Takagi, K; Ueda, T; Urasaki, Y; Yamauchi, T; Yoshida, A, 2009) |
| "Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor." | ( Borthakur, G; Cortes, JE; Estey, EE; Faderl, S; Jain, N; Kantarjian, H; Lin, E; O'Brien, S; Pierce, S; Ravandi, F, 2009) |
| "We hypothesized that TLR7/8 agonist treatment of human acute myeloid leukemia (AML) cells would lead to an increased immunogenicity of AML cells." | ( Berneman, ZN; Cools, N; Lion, E; Ponsaerts, P; Smits, EL; Van Camp, K; Van Tendeloo, VF, 2010) |
| "To improve long-term outcome of de novo acute myeloid leukemia (AML) patients by intermediate dose of cytarabine integrated in induction therapy and to explore the impact of cytogenetic abnormalities on the prognosis." | ( Bian, S; Fu, M; Lin, D; Liu, J; Mi, Y; Wang, J; Wang, Y; Yu, W, 2009) |
| "In conclusion, treatment for relapsed acute myeloid leukemia with modified CAG regiment is safe and effective, and can provide conditions for allo-hematopoietic stem cell transplantation, but its long term efficacy needs to further study." | ( Chai, JY; Wei, N; Zheng, WQ, 2009) |
| "Patients with relapsed or untreated acute myeloid leukemia who were not candidates for chemotherapy entered one of the two treatment arms." | ( DiPersio, JF; Espinoza-Delgado, I; Gore, SD; Juckett, M; Laumann, K; Loaiza-Bonilla, A; Roy, V; Schaefer, EW; Slack, J; Wu, W, 2009) |
| "Red blood cells from acute myeloid leukemia patients and healthy donors were treated with daunorubicin as well as all-trans-retinoic acid, arsenic trioxide or etoposide for 0-48 h." | ( Gilbert, GE; Hou, J; Lu, C; Qi, S; Qiao, X; Shi, J; Yu, H; Zheng, Y; Zhou, J, 2010) |
| "The mainstay of acute myeloid leukemia chemotherapy is the nucleoside analog cytarabine (ara-C)." | ( Lamba, JK, 2009) |
| "The fundamental principle of the treatment of AML (acute myeloid leukemia) is "total cell kill." | ( Ozawa, K, 2009) |
| "Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome undergoing induction chemotherapy or first salvage were eligible." | ( Alvarado, G; Blamble, D; Cortes, J; Faderl, S; Hernandez, M; Kantarjian, H; Koller, C; Mattiuzzi, GN; Pierce, S; Verstovsek, S; Xiao, L, 2011) |
| "Older patients with acute myeloid leukemia (AML) have limited treatment options because of the lack of effectiveness and the toxicity of available therapies." | ( Cashen, AF; DiPersio, JF; O'Donnell, MR; Schiller, GJ, 2010) |
| "PURPOSE In patients with acute myeloid leukemia (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine." | ( Bordessoule, D; Bourhis, JH; Castaigne, S; Chevret, S; Contentin, N; Corm, S; de Revel, T; Dombret, H; Fenaux, P; Gardin, C; Merabet, F; Michallet, M; Pautas, C; Preudhomme, C; Raffoux, E; Reman, O; Rousselot, P; Terré, C; Thomas, X; Turlure, P, 2010) |
| "The search terms used were: acute myeloid leukemia in conjunction with treatment, chemotherapy, stem cell transplantation, and immunotherapy." | ( Robak, T; Wierzbowska, A, 2009) |
| "Treatment of acute myeloid leukemia (AML) remains challenging with many patients harboring unfavorable prognostic parameters such as FLT3 internal tandem duplication (FLT3-ITD) mutations leading to a constitutively activated FLT3-receptor tyrosine kinase (RTK)." | ( Ehninger, G; Koch, S; Mohr, B; Oelschlägel, U; Steudel, C; Stölzel, F; Thiede, C, 2010) |
| "To investigate the current status of acute myeloid leukemia (AML) treatment in Shanghai." | ( , 2010) |
| "Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse." | ( Bradstock, K, 2006) |
| "Therapy-related acute myelogenous leukemia (t-AML) is a generally fatal disease with a very poor response to conventional chemotherapy." | ( Calixto, R; Domingues, M; Florêncio, R; Maior, AP; Ostronoff, F; Ostronoff, M; Sucupira, A, 2011) |
| "In conclusion, patients with acute myeloid leukemia receiving chemotherapy should be monitored for active CMV infection." | ( Capobianchi, A; Capria, S; Cardarelli, L; Foà, R; Gentile, G; Gianfelici, V; Martino, P; Meloni, G; Trisolini, SM, 2010) |
| "Patients with newly diagnosed acute myeloid leukemia (AML) often have residual leukemia in the bone marrow 10 to 14 days after the start of induction therapy." | ( Cassileth, PA; Kim, HT; Lazarus, HM; Litzow, MR; Rowe, JM; Tallman, MS; Wiernik, PH, 2010) |
| "Finding an effective treatment for acute myeloid leukemia (AML) remains a challenge, and all cellular processes that are deregulated in AML cells should be considered in the design of targeted therapies." | ( Arnoult, C; Bardet, V; Bouscary, D; Boyer, O; Chapuis, N; Dreyfus, F; Foretz, M; Green, AS; Hermine, O; Ifrah, N; Lacombe, C; Lambert, M; Maciel, TT; Mayeux, P; Moura, IC; Park, S; Tamburini, J; Viollet, B; Willems, L, 2010) |
| "The need for new treatment options for acute myeloid leukemia (AML) is increasing." | ( Cros-Perrial, E; Demangel, D; Dreano, M; Dumontet, C; Herveau, S; Jordheim, LP; Keime, C; Plesa, A; Vendrell, JA, 2011) |
| "The majority of patients with acute myeloid leukemia (AML) will require second-line chemotherapy for either relapsed or refractory disease." | ( Alizadeh, AA; Berube, C; Coutre, S; Gotlib, J; Ho, M; Kohrt, HE; Liedtke, M; Majeti, R; Medeiros, BC; Owen, T; Patel, S; Pollyea, DA, 2010) |
| "Older patients with acute myeloid leukemia (AML) have limited treatment options and a poor prognosis, thereby warranting novel therapeutic strategies." | ( Abboud, CN; Cashen, AF; Demland, J; DiPersio, JF; Fehniger, TA; Nelson, AD; Stockerl-Goldstein, KE; Trinkaus, K; Uy, GL; Vij, R; Westervelt, P, 2011) |
| "Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction chemotherapy." | ( Aurelius, J; Brune, M; Hellstrand, K; Martner, A; Söderholm, J; Thorén, FB, 2010) |
| "A 7-month-old girl with acute myeloid leukemia (AML) developed acute respiratory distress syndrome (ARDS) during the pancytopenic period after induction chemotherapy." | ( Goto, M; Kakihana, Y; Kawano, Y; Kodama, Y; Nishikawa, T; Okamoto, Y; Shinkoda, Y; Tanabe, T, 2011) |
| "the results of conventional treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remain poor and innovative strategies are warranted." | ( Prebet, T; Vey, N, 2011) |
| "Among 161 patients with acute myeloid leukemia (non-M5 subtype), estimated median overall survival was 39, 29, and 37 months, respectively, in the daunorubicin, standard-dose homoharringtonine, and high-dose homoharringtonine treatment groups (P = ." | ( Huang, BT; Liu, XL; Xiao, Z; Yu, J; Zeng, QC; Zhu, HQ, 2012) |
| "We examined in vivo FLT3 inhibition in acute myeloid leukemia patients treated with chemotherapy followed by the FLT3 inhibitor lestaurtinib, comparing newly diagnosed acute myeloid leukemia patients with relapsed patients." | ( Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X, 2011) |
| "The most effective regimen for acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after two different courses of front-line chemotherapy has not been established." | ( Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ, 2011) |
| "Co-treatment with VPA and bortezomib on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cell lines resulted in marked inhibition of proliferation and induction of apoptosis, including a striking increase in mitochondrial injury, caspase cascade activation, and altered expression of Bcl-2 family proteins." | ( Chen, L; Li, JM; Shen, ZX; Wang, AH; Wei, L; Wu, WL; Zhao, SQ, 2011) |
| "Pediatric acute myeloid leukemia (AML) remains a challenging disease to treat even with intensified cytarabine-based chemotherapy." | ( Buck, SA; Edwards, H; Ge, Y; Xie, C; Xu, X; Zhou, H, 2011) |
| "They often transform to acute myeloblastic leukemia (AML), which is difficult to treat and carries a dismal prognosis." | ( de Marcos, NS; Font, P; Molina, CA; Rodríguez, MJ, 2011) |
| "Cytotoxic chemotherapy regimens for acute myelogenous leukemia and profound neutropenia were significantly associated with IFI (P=0." | ( Kato, K; Kojima, S; Matsumoto, K; Watanabe, N, 2011) |
| "We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA)." | ( Adès, L; Beyne-Rauzy, O; Cluzeau, T; Dreyfus, F; Fenaux, P; Fontenay, M; Gelsi-Boyer, V; Itzykson, R; Kosmider, O; Mansat-De Mas, V; Preudhomme, C; Quesnel, B; Raynaud, S; Vey, N, 2011) |
| "Older acute myeloid leukemia (AML) patients with a chromosome 5q deletion have poor outcomes with conventional chemotherapy." | ( Advani, A; Appelbaum, FR; Gundacker, H; Lancet, J; Liesveld, J; List, AF; Mulford, D; Norwood, T; Petersdorf, S; Sekeres, MA; Willman, CL, 2011) |
| "Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT)." | ( Andreeff, M; Bashir, Q; Bayraktar, UD; Champlin, RE; Chen, J; Chiattone, A; Cortes, J; de Lima, M; Giralt, S; Kantarjian, H; Kebriaei, P; Konopleva, M; McCue, D; Qazilbash, M; Ravandi, F; Sharma, M, 2011) |
| "Thirteen patients with acute myeloid leukemia, 5 with active disease, 2 in molecular relapse, and 6 in morphologic complete remission (CR; median age, 62 years; range, 53-73 years) received highly purified CD56(+)CD3(-) natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor-ligand mismatched donors after fludarabine/cyclophosphamide immunosuppressive chemotherapy, followed by IL-2." | ( Baccarani, M; Bandini, G; Bontadini, A; Curti, A; D'Addio, A; Dan, E; Fruet, F; Giudice, V; Isidori, A; Lemoli, RM; Martinelli, G; Motta, MR; Paolini, S; Parisi, S; Ruggeri, L; Trabanelli, S; Urbani, E; Velardi, A, 2011) |
| "Chemotherapy for elderly patients with acute myeloid leukemia (AML) results in a median overall survival (OS) of ≤ 1 year." | ( Berdel, WE; Brunnberg, U; Büchner, T; Dührsen, U; Dürk, HA; Ehninger, G; Kessler, T; Kosch, M; Koschmieder, S; Krug, U; Mesters, RM; Mohr, M; Müller-Tidow, C; Noppeney, R; Sauerland, MC; Schulz, C; Serve, H, 2012) |
| "The treatment of older adults with acute myeloid leukemia (AML) is associated with unsatisfactory rates of response and overall survival." | ( Cannas, G; Chelghoum, Y; Ducastelle, S; Dumontet, C; Elhamri, M; Labussière, H; Michallet, M; Nicolini, F; Thomas, X; Tigaud, I, 2011) |
| "To evaluate the outcomes of acute myeloid leukemia patients who were older than 60 years of age at the time of diagnosis following the implementation of a treatment algorithm based on age, performance status, and cytogenetic results." | ( Barroso, RS; Chauffaille, ML; Ribeiro, JC; Sandes, AF; Silva, MR, 2011) |
| "Patients with core binding factor acute myeloid leukemia (CBF-AML) benefit from more intensive chemotherapy, but whether both the t(8;21) and inv(16)/t (16;16) subtypes requires intensification remained to be determined." | ( Bourquin, JP; Corbacioglu, S; Creutzig, U; Dworzak, MN; Reinhardt, D; Sander, A; Schrauder, A; Stary, J; Teigler-Schlegel, A; von Neuhoff, C; Zimmermann, M, 2011) |
| "A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and -2004 (n = 66)." | ( Bourquin, JP; Creutzig, U; Dworzak, MN; Kremens, B; Lehrnbecher, T; Reinhardt, D; Sander, A; Schmid, I; Starý, J; Steinbach, D; von Neuhoff, C; von Stackelberg, A; Vormoor, J; Zimmermann, M, 2012) |
| "In addition, we demonstrated that treatment of human acute myeloid leukemia cell line MV4-11 with the selective HDAC6 inhibitors decreases levels of mutant FLT-3 and constitutively active STAT5 and attenuates Erk phosphorylation, all of which are associated with the inhibitor's selective toxicity against leukemia." | ( Chou, CJ; Inks, ES; Jesinkey, SR; Josey, BJ, 2012) |
| "The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting." | ( Brugger, W; Claus, R; Deschler, B; Döhner, H; Döhner, K; Galm, O; Ganser, A; Germing, U; Hackanson, B; Hagemeijer, A; Heil, G; Kuendgen, A; Lübbert, M; Platzbecker, U; Rethwisch, V; Rüter, BH; Schmid, M; Schmoor, C; Wijermans, PW, 2012) |
| "Recently, strategies for acute myeloid leukemia (AML) therapy have been developed that target anti-apoptotic BCL2 family members using BH3-mimetic drugs such as ABT-737." | ( Andreeff, M; Bergamo, P; Bornmann, W; Chen, W; Konopleva, M; Korchin, B; Mak, DH; McCubrey, J; McQueen, T; Milella, M; Ricciardi, MR; Ruvolo, P; Tafuri, A; Tsao, T; Watts, JC, 2012) |
| "Prognosis of patients with acute myeloid leukemia (AML) remains poor despite the use of first-line induction chemotherapy." | ( Bunte, RM; Chiu, GN; Chng, WJ; Ling, LU; Tan, KB, 2012) |
| "Despite recent progress in the treatment of acute myeloid leukemia (AML), the prognosis of this rather heterogeneous disease remains poor and novel chemotherapeutics that specifically target leukemic cells must be developed." | ( Baud, V; Billot, K; Boehrer, S; Fenaux, P; Galluzzi, L; Kepp, O; Kroemer, G; Lainey, E; Métivier, D; Sébert, M; Senovilla, L; Tailler, M; Thépot, S, 2012) |
| "Do patients with therapy-related acute myeloid leukemia (t-AML) have a poor prognosis independent of other predictive variables such as cytogenetics or molecular determinants? Limited data exist to answer this question in part because t-AML is often considered together with AML following myelodysplastic syndromes (MDS) in the category of secondary AML." | ( Feldman, EJ, 2011) |
| "Standard therapy for older patients with acute myeloid leukemia (AML) has a poor outcome." | ( Borthakur, G; Burger, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Ravandi, F; Wang, X, 2012) |
| "The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse." | ( Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P, 2012) |
| "The patients were under treatment for acute myeloid leukemia and their blood cultures yielded B." | ( Aydın, N; Bolaman, Z; Eyigör, M; Gültekin, B; Kadıköylü, G; Yavaşoğlu, I, 2012) |
| "We describe a child with acute myeloid leukemia (AML) who developed severe central sleep apnea (CSA) on methadone therapy for chronic pain management." | ( Amos, LB; D'Andrea, LA, 2013) |
| "The treatment of acute myeloid leukemia has not changed significantly over the last 40 years." | ( Cortes, J; Daver, N, 2012) |
| "Although the treatment of acute myeloid leukemia (AML) has improved substantially in the past three decades, more than half of all patients develop disease that is refractory to intensive chemotherapy." | ( Byers, RJ; Christensen, JG; Christie, A; Dahlberg, SE; Delwel, R; Kentsis, A; Kung, AL; Kutok, JL; Licht, JD; Look, AT; Moreau, LA; Ngo, V; Reed, C; Rice, KL; Rodig, SJ; Sanda, T; Staudt, LM; Tholouli, E; Valk, PJ; Vande Woude, G, 2012) |
| "The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed." | ( Bloomfield, CD; Blum, W; Bundschuh, R; Byrd, JC; Caligiuri, MA; Curfman, J; Frankhouser, D; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Klisovic, R; Marcucci, G; Metzeler, K; Murphy, M; Rodriguez, B; Tam, HH; Trimarchi, M; Walker, A; Whitman, SP; Wu, YZ; Yan, P, 2012) |
| "We present 3 patients with acute myeloid leukemia and PM who were treated with radical surgical debridement combined with high-dose liposomal amphotericin B (LAB), and subsequently underwent successful allogeneic HCT." | ( Bethge, W; Faul, C; Fend, F; Horger, M; Kanz, L; Nann, D; Schneidawind, D; Vogel, W, 2012) |
| "Recent data suggest that the risk of acute myeloid leukemia (AML) progression of del(5q) patients is dependent on their individual risk factors before treatment initiation, including World Health Organization (WHO) prognostic scoring system parameters and TP53 mutations." | ( Giagounidis, AA, 2012) |
| "The most effective regimen for relapsed acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after a course of salvage therapy has not been established." | ( Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C, 2012) |
| "It finally revealed a therapy-related acute myeloid leukemia, secondary to previous chemotherapy for a testicular tumor." | ( Fux-Arnold, C; Gavillet, M; Medinger, M; Tichelli, A, 2012) |
| "Despite efforts to understand and treat acute myeloid leukemia (AML), there remains a need for more comprehensive therapies to prevent AML-associated relapses." | ( Cho, EE; Corey, SJ; Cusimano, M; Dassonville-Klimpt, A; Datti, A; Dick, JE; Dissanayake, D; Eaves, C; Ellis, WY; Eppert, K; Gebbia, M; Giaever, G; Gronda, M; Hurren, R; Jhas, B; Jonet, A; Lee, AY; Li, X; MacLean, N; Minden, MD; Nislow, C; Ohashi, PS; Prabha, S; Rogers, I; Rutledge, AC; Schimmer, AD; Seneviratne, A; Sharmeen, S; Skrtic, M; Sonnet, P; Spagnuolo, PA; Sriskanthadevan, S; Sukhai, MA; Sun, H; Urbanus, M; Wang, JC; Wang, X; Wrana, J, 2013) |
| "To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive generations of Stanford clinical trials." | ( Advani, RH; Balise, R; Greenberg, PL; Hoppe, RT; Horning, SJ; Koontz, MZ; Rosenberg, SA, 2013) |
| "Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy." | ( Berdel, WE; Brandts, CH; Büchner, T; Bug, G; Dührsen, U; Ehninger, G; Gerss, J; Koschmieder, A; Koschmieder, S; Krug, U; Müller-Tidow, C; Noppeney, R; Röllig, C; Schaich, M; Schwammbach, D; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Tidow, N, 2012) |
| "Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of <20,000/µl at the time of study entry and adequate organ function were eligible." | ( Berdel, WE; Brandts, CH; Büchner, T; Bug, G; Dührsen, U; Ehninger, G; Gerss, J; Koschmieder, A; Koschmieder, S; Krug, U; Müller-Tidow, C; Noppeney, R; Röllig, C; Schaich, M; Schwammbach, D; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Tidow, N, 2012) |
| "In pediatric relapsed acute myeloid leukemia (AML), optimal reinduction therapy is unknown." | ( Aleinikova, O; Armendariz, H; Bertrand, Y; Creutzig, U; Dworzak, M; Gibson, BE; Ha, SY; Hasle, H; Hovi, L; Kaspers, GJ; Leverger, GG; Maschan, A; Razzouk, BI; Reinhardt, D; Rizzari, C; Smisek, P; Smith, O; Stark, B; Tamminga, RY; Zimmermann, M, 2013) |
| "Cytarabine (ara-C) is the key agent for treating acute myeloid leukemia." | ( Negoro, E; Nishi, R; Takemura, H; Ueda, T; Yamauchi, T, 2013) |
| "To date, acute myeloid leukemia (AML) shows very poor outcome for conventional chemotherapy." | ( Chen, Y; Ding, Q; Gu, R; Liang, J; Zhang, X, 2013) |
| "Eighteen of 21 patients with acute myelogenous leukemia (AML) treated on study completed planned therapy." | ( Anyang, BN; Baer, MR; Beumer, JH; Carrier, F; Espinoza-Delgado, I; Fang, HB; Gojo, I; Lapidus, R; Ross, DD; Sadowska, M; Srivastava, RK; Tan, M, 2013) |
| "Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell reduction, however a marginal decrease in bone marrow blasts." | ( Galinsky, I; Gray, N; Griffin, JD; Liu, F; Liu, Q; Mitsiades, C; Nelson, E; Nicolais, M; Nonami, A; Sattler, M; Smith, RW; Stone, R; Weisberg, E; Zhang, J; Zhang, X, 2013) |
| "DNA methylation plays a critical role in acute myeloid leukemia (AML) development, and presents an excellent target for treatment of this disease." | ( Chan, KK; Chiu, M; Deng, Y; Grever, MR; He, S; He, X; Hughes, T; Liu, S; Liu, Z; Mo, X; Peng, Y; Wang, QE; Wu, LC; Xie, Z; Yu, J, 2013) |
| "A 23-year-old man with acute myelogenous leukemia (AML) (M2) who was pretreated with chemotherapy for autologous bone marrow transplantation developed a skin ulcer on the left groin." | ( Chen, H; Hu, J; Hu, L; Jiang, M; Li, B; Li, Y; Lou, X; Ning, H; Wang, J; Xu, C; Yu, Z, 2013) |
| "A 43-year-old patient with recurrent acute myeloid leukemia (AML) was treated with high-dose cytarabine." | ( Ham, JC; Ruijs, GJ; van Marwijk Kooy, MR, 2013) |
| "Overexpression of XIAP is common in acute myeloid leukemia (AML) and other cancers and is thought to cause resistance to cancer therapy." | ( Borthakur, G; Carter, BZ; Katragadda, L, 2013) |
| "Elderly patients with acute myeloid leukemia (AML) have a poor outcome because of co- morbidities, poor tolerance to intensive chemotherapy and inherently more resistant disease." | ( Aleem, A; Algahtani, F; Almomen, A; Alsaleh, K; Anjum, F; Iqbal, Z, 2013) |
| "Studies of survival outcomes in acute myeloid leukemia (AML) patients treated with allogeneic haematopoietic stem cell transplantation (HSCT) are essential for planning patient care." | ( Azlan, H; Mangantig, E; Naing, NN; Norsa'adah, B, 2013) |
| "However, disease progression to acute myeloid leukemia (AML) was observed after an additional two courses of azacitidine, which was resistant to induction chemotherapy." | ( Ichikawa, M; Iizuka, H; Kurokawa, M; Masuda, A; Nannya, Y; Yamamoto, G; Yatomi, Y; Yoshimi, A, 2013) |
| "Treatment of acute myeloid leukemia remains a therapeutic challenge." | ( Fischer, T; Heidel, FH; Jentsch-Ullrich, K; Krogel, C; Luehr, H; Schalk, E; Schnoeder, TM; Wolleschak, D, 2013) |
| "Outcomes in acute myeloid leukemia (AML) remain unsatisfactory, and novel treatments are urgently needed." | ( Benjamin, DR; Bernstein, ID; Burke, PJ; Drachman, JG; Harrington, KH; Jeffrey, SC; Klussman, K; Kostner, H; Kung Sutherland, MS; Lyon, RP; McEarchern, JA; Meyer, D; Ryan, MC; Senter, PD; Stone, I; Sussman, D; Walter, RB; Westendorf, L; Yu, C; Zeng, W, 2013) |
| "The prognosis of acute myeloid leukemia (AML) in elderly (≥65 years) patients is poor and treatment remains non-consensual especially for those who are not eligible for intensive therapies." | ( Alkhaeir, S; Callens, C; Damaj, G; Dussiot, M; Gorin, NC; Hermine, O; Isnard, F; Marolleau, JP; Monteiro, RC; Moura, IC; Paubelle, E; Rubio, MT; Suarez, F; Zylbersztejn, F, 2013) |
| "De novo acute myeloid leukemia with normal karyotype (NK-AML) comprises a large group of patients with no common cytogenetic alterations and with a large variation in treatment response." | ( Falk, IJ; Fyrberg, A; Gréen, H; Hermanson, M; Höglund, M; Lotfi, K; Nahi, H; Palmqvist, L; Paul, E; Rosenquist, R; Stockelberg, D; Wei, Y, 2013) |
| "The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy." | ( Aulitzky, W; Berdel, WE; Blau, I; Brandts, C; Brunnberg, U; Duyster, J; Ehninger, G; Fischer, T; Giagounidis, A; Heinecke, A; Krämer, A; Kreuzer, KA; Krug, U; Kunzmann, V; Müller-Tidow, C; Neubauer, A; Noppeney, R; Ottmann, O; Reichle, A; Sauerland, MC; Schaich, M; Serve, H; Steffen, B; Stuhlmann, R; Thiede, C; Wagner, R; Wandt, H, 2013) |
| "Through transcriptome analysis of human acute myeloid leukemia THP1 cells treated with a tranylcypromine-derivative inhibitor of LSD1 active in the low nanomolar range, we identified the cell surface marker CD86 as a sensitive surrogate biomarker of LSD1 inhibition." | ( Cockerill, MJ; Hitchin, JR; Lynch, JT; Somervaille, TC; Wiseman, DH, 2013) |
| "PRAME expression was further enhanced in acute myeloid leukemia cell lines after combined treatment with chidamide and DNA demethylating agent decitabine." | ( Gao, X; Jiang, M; Ning, Q; Wang, J; Wang, L; Yao, Y; Yu, L; Zhou, J, 2013) |
| "Adults with relapsed/refractory acute myeloid leukemia (n = 14) and acute lymphoid leukemia (n = 6) were treated with dinaciclib 50 mg/m(2) given as a 2-h infusion every 21 days." | ( Baer, MR; Bannerji, R; Feldman, EJ; Gojo, I; Iyer, SP; Jou, YM; Lapidus, RG; Poon, J; Sadowska, M; Sausville, EA; Small, K; Walker, A; Zhang, D; Zhu, Y, 2013) |
| "In another nine acute myeloid leukemia or myelodysplastic syndrome patients, it was noted that the expression of NXF2 was upregulated in all patients following the first cycle of decitabine, which suggested that NXF2 was activated by decitabine treatment in vivo." | ( Gao, L; Gao, X; Jiang, M; Li, J; Li, Y; Luo, X; Wang, L; Yao, Y; Yu, L; Zhou, J; Zhou, M, 2013) |
| "Elderly acute myeloid leukemia (AML) patients and patients with higher-risk myelodysplastic syndromes (MDS) have a much poorer prognosis than younger patients despite intensive chemotherapy." | ( Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Kobayashi, S; Kodaira, H; Matsukawa, Y; Miura, K; Takahashi, H; Takeuchi, J; Uchino, Y, 2013) |
| "Therapy-related acute myeloid leukemia (t-AML) is an increasingly recognized sequela in patients receiving chemotherapy or radiotherapy for a primary malignancy or autoimmune disease." | ( Advani, A; Elson, P; Kalaycio, M; Kendeigh, C; Maciejewski, JP; Mohan, S; Mukherjee, S; Ornstein, MC; Saunthararajah, Y; Sekeres, MA; Tiu, RV, 2014) |
| "A 48-year-old man with a newly diagnosed acute myeloid leukemia developed purpuric rash on day 6 after chemotherapy." | ( Clark, LN; Deloney, LA; McDonald, JE; Zhu, HJ, 2014) |
| "Secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/sAML) are the most serious secondary events occurring after immunosuppressive therapy in patients with aplastic anemia." | ( Baumann, I; Führer, M; Furlan, I; Göhring, G; Niemeyer, CM; Nöllke, P; Schlegelberger, B; Schwarz, S; Strahm, B; Teigler-Schlegel, A; Walther, JU; Yoshimi, A, 2014) |
| "Here, we demonstrate that acute myeloid leukemia (AML) cell lines, primary patient samples, and murine primary xenografts are very sensitive to treatment with the selective BCL-2 antagonist ABT-199." | ( Andreeff, M; Benito, JM; Borthakur, G; Bucci, D; Cortes, J; DeAngelo, DJ; Debose, L; Döhner, H; Gaidzik, VI; Galinsky, I; Golfman, LS; Haferlach, T; Han, L; Harutyunyan, KG; Hogdal, LJ; Hu, J; Kantarjian, H; Konopleva, M; Letai, AG; Leverson, JD; Marcucci, G; Mu, H; Müschen, M; Newman, R; Pan, R; Park, E; Ruvolo, PP; Ruvolo, V; Ryan, J; Schindela, S; Stone, RM; Zweidler-McKay, P, 2014) |
| "We found that the apoptotic rate of acute myeloid leukemia (AML) subtype M2 (AML-M2) cell line Kasumi-1 treated by UA was higher than those of other leukemia cell lines, but was not as high as that treated by arabinofuranosyl cytidine (Ara-C), suggesting that UA is an important chemotherapeutic agent to treat AML-M2." | ( Fang, Q; Hu, X; Li, Y; Ma, D; Sun, J; Wang, J; Wang, P; Zhang, Y; Zhou, S, 2014) |
| "For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor." | ( Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E, 2014) |
| "Therapy-related acute myeloid leukemia and myelodysplastic syndromes (t-AML/MDS) represent severe late effects in patients treated for Hodgkin lymphoma (HL)." | ( Behringer, K; Böll, B; Borchmann, P; Diehl, V; Eichenauer, DA; Engert, A; Franklin, J; Fuchs, M; Halbsguth, T; Haverkamp, H; Klimm, B; Rothe, A; Sasse, S; Thielen, I; von Tresckow, B, 2014) |
| "We provide evidence that concomitant treatment of acute myeloid leukemia (AML) cells or chronic myeloid leukemia (CML) cells with resveratrol potentiates arsenic trioxide-dependent induction of apoptosis." | ( Altman, JK; Beauchamp, E; Eklund, EA; Goussetis, DJ; Kosciuczuk, EM; Platanias, LC; Wu, EJ, 2014) |
| "Novel therapies for the treatment of acute myeloid leukemia are required to overcome disease resistance and to provide potentially less toxic therapies for older adults." | ( Amrein, PC; Berchuck, J; Deangelo, DJ; Galinsky, I; Golub, T; Neuberg, D; Sirulnik, LA; Stegmaier, K; Stone, RM; Wadleigh, M, 2014) |
| "Treatment with daunorubicin (DNR) in acute myeloid leukemia is moderately effective and associated with significant side effects, including cardiac toxicity." | ( Chen, M; Haddad, AS; Henderson, PT; Jonas, BA; Lam, KS; Li, Y; Lin, TY; Liu, R; Pan, CX; Xiao, K; Xiao, W; Zhang, H, 2014) |
| "Intensive chemotherapy for pediatric acute myeloid leukemia incurs the risk of infectious complications, but the benefits of antibiotic prophylaxis remain unclear." | ( Avutu, V; Cao, X; Flynn, PM; Gaur, AH; Hayden, RT; Howard, SC; Inaba, H; Marszal, LN; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE, 2014) |
| "The treatment of young patient with acute myeloid leukemia (AML) has improved dramatically during the past several decades." | ( Chen, C; Xu, W; Yang, J, 2015) |
| "From 2007 to 2013, 173 patients with acute myeloid leukemia were treated." | ( Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z, 2014) |
| "Chemotherapeutic drugs used in the treatment of acute myeloid leukemias (AMLs) are thought to induce cancer cell death through the generation of DNA double-strand breaks." | ( Baik, H; Bossis, G; Boutzen, H; Brockly, F; Kaoma, T; Kifagi, C; Manenti, S; Pelegrin, M; Piechaczyk, M; Récher, C; Ristic, M; Saland, E; Salem, T; Sarry, JE; Vallar, L; Vergez, F, 2014) |
| "Elderly acute myelocytic leukemia (AML) patients have limited treatment options because they poorly tolerate standard-dose chemotherapy." | ( Cai, L; Chi, X; Li, S; Lu, X; Tuo, S; Wang, H; Wang, X; Wu, X; Yang, B; Yang, Y; Yu, R; Zhang, F; Zhu, H, 2014) |
| "We describe a patient diagnosed with acute myeloid leukemia (AML) and low activity of thiopurine methyltransferase (TPMT) who developed secondary myelodysplastic syndrome after treatment." | ( Hasle, H; Kjeldsen, E; Nersting, J; Schmiegelow, K; Stensman, LM, 2015) |
| "Rates of therapy related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) (5." | ( Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lerner, S; O'Brien, S; Qiao, W; Strom, SS; Trinh, L; Wang, X; Wierda, W, 2015) |
| "The mechanisms underlying acute myeloid leukemia (AML) treatment failure are not clear." | ( He, C; Mao, ZJ; Singleton, TP; Su, G; Tan, D; Wei, L; Yin, B; Zhao, W; Zheng, Y, 2014) |
| "Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options." | ( Erlichman, C; Flynn, PJ; Juckett, MB; Jumonville, A; LaPlant, B; Mattison, R; Moreno-Aspitia, A, 2015) |
| "Adult patients with acute myeloid leukemia and myelodysplastic syndrome on induction therapy or allogeneic hematopoietic stem cell transplant recipients were randomized (1:1 ratio) to 1 of 2 arms: "GM-PCR group" (the results of serial serum GM and PCR assays were provided to treating physicians) and "GM group" (only the results of serum GM were informed)." | ( Aguado, JM; Barba, P; Batlle, M; Cuenca-Estrella, M; Fernández-Ruiz, M; Gallardo, D; Heras, I; López-Jiménez, J; Olave, T; Parody, R; Polo, M; Rovira, M; Ruiz-Camps, I; Silva, JT; Solano, C; Vallejo, C; Varela, R; Vázquez, L; Villaescusa, T, 2015) |
| "Detection of NPM1 mutations in acute myeloid leukemia (AML) is important for risk stratification, treatment decision, and therapeutic monitoring." | ( Ki, CS; Kim, HJ; Kim, JW; Kim, SH; Lee, ST; Shin, SY, 2015) |
| "In adults with non-promyelocytic acute myeloid leukemia (AML), high-dose cytarabine consolidation therapy has been shown to influence survival in selected patients, although the appropriate doses and schemes have not been defined." | ( Azevedo, MC; Buccheri, V; Chamone, DA; Dorlhiac-Llacer, PE; Velloso, ED, 2015) |
| "The role of ABCB1 polymorphisms in acute myeloid leukemia (AML) outcomes of standard chemotherapy (cytarabine plus anthracyclines) remains controversial." | ( Aliño, SF; Bosó, V; Herrero, MJ; Megías-Vericat, JE; Montesinos, P; Moscardó, F; Poveda, JL; Rojas, L; Sanz, MÁ, 2015) |
| "The prognosis of acute myeloid leukemia (AML) is poor, highlighting the need for novel treatments." | ( Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X, 2015) |
| "Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodysplastic syndrome or after antineoplastic therapy, responds poorly to current therapies." | ( Allen, SL; Damon, L; Egyed, M; Erba, HP; Horst, HA; Jang, JH; Lundberg, AS; Masszi, T; Mazzola, E; Neuberg, D; Pigneux, A; Powell, B; Rizzieri, D; Sekeres, MA; Selleslag, D; Solomon, SR; Stone, RM; Stuart, RK; Tallman, MS; Venugopal, P; Warzocha, K; Wetzler, M, 2015) |
| "We treated a 71-year-old woman with acute myeloid leukemia (AML-M5a) with low-dose cytarabine, acralubicin, and filgrastim as the induction therapy." | ( Hiramoto, N; Itoh, K; Kamei, K; Kodaka, T; Nishimori, M; Suzuki, E; Takahashi, T; Takegawa, H; Tsunemine, H; Yarita, K, 2014) |
| "Intensifying treatment for pediatric acute myeloid leukemia (AML) has improved survival, with infections now being a leading cause of morbidity." | ( Felsenstein, S; Fu, C; Hoffman, JA; Orgel, E; Rushing, T, 2015) |
| "Older patients with acute myeloid leukemia (AML) have poor outcomes with standard induction chemotherapy." | ( Ford, LA; Gandhi, S; Griffiths, EA; Gupta, N; Miller, A; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M, 2015) |
| "The treatment of older adults with acute myeloid leukemia (AML) using standard intensive chemotherapy has been associated with poor outcomes." | ( Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X, 2015) |
| "Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby improving survival." | ( Burnett, AK; Cahalin, P; Cavenagh, J; Clark, RE; Dennis, M; Friis, L; Hills, RK; Kell, J; Kjeldsen, L; McMullin, MF; Milligan, D; Russell, NH; Thomas, IF, 2015) |
| "Treatment of acute myeloid leukemia (AML) remains difficult owing to the development of treatment resistance, which might be overcome through antagonists of inhibitors of apoptosis proteins (IAPs)." | ( Brill, JM; DiPersio, JF; Erba, HP; Larson, RA; Luger, SM; Rouits, E; Sorensen, JM; Tallman, MS; Vuagniaux, G; Zanna, C, 2015) |
| "Although acute myeloid leukemia (AML) exhibits diverse responses to chemotherapy, patients harboring the t(8;21) translocation are part of a favorable risk group." | ( Cho, KM; Hwang, SY; Kim, HJ; Kim, NY; Kim, TS; Kim, YK; Lee, TH; Song, JH, 2015) |
| "The incidence of acute myeloid leukemia (AML) is rising and the outcome of current therapy, which has not changed significantly in the last 40 years, is suboptimal." | ( Bhatnagar, V; Carter-Cooper, B; Emadi, A; Lapidus, RG; Levis, MJ; Sadowska, M; Sausville, EA; van der Merwe, I, 2015) |
| "Cytogenetically normal acute myeloid leukemia (CN-AML) patients harboring RUNX1 mutations have a dismal prognosis with anthracycline/cytarabine-based chemotherapy." | ( Ashton, JM; Balys, M; Becker, MW; Calvi, LM; Eberhardt, A; Mendler, JH; Myers, JR; Sivagnanalingam, U; Wang, N, 2015) |
| "Interestingly, the estimated time to acute myeloid leukemia transformation was 30 months, which refers to patients who responded to AZA treatment or remained stable." | ( Bazani, E; Bouchla, A; Dimitriadis, G; Foukas, P; Ioannidou, ED; Kefala, M; Kontos, CK; Papageorgiou, SG; Pappa, V; Vasilatou, D, 2016) |
| "Treatment failure in acute myeloid leukemia (AML) is frequently due to the persistence of a cell population resistant to chemotherapy through different mechanisms, in which drug efflux via ATP-binding cassette (ABC) proteins, specifically P-glycoprotein, is one of the most recognized." | ( Altmann, KH; Ambati, S; Calvo-Vidal, MN; Cerchietti, L; Díaz, JF; Fang, W; Jordi, M; Kahn, A; Moore, MAS; Pera, B, 2015) |
| "From April 1996 to January 2006 our acute myeloid leukemia treatment regimen included induction and consolidation therapy with cytosine arabinoside, anthracyclines and etoposide, followed by HDM and autologous stem cell infusion." | ( Ben-Haroush, A; Even-Or, E; Stein, J; Yahel, A; Yaniv, I, 2016) |
| "A 4-year-old girl with history of acute myeloid leukemia post chemotherapy and stem cell transplant presented with pancytopenia." | ( Elojeimy, S; Luana Stanescu, A; Parisi, MT, 2016) |
| "Treatment for acute myeloid leukemia has remained cytarabine and an anthracycline given in the standard 3 + 7 regimen." | ( Barker, JA; Bixby, D; Marini, BL; Perissinotti, AJ, 2016) |
| "Although the occurrence of acute myeloid leukemia (AML) after chemotherapy for multiple myeloma (MM) is common in clinical settings, the simultaneous occurrence of these malignancies in patients without previous exposure to chemotherapy is a rare event." | ( Fang-Lin, L; Hao, L; Ling-Ling, W; Lu-Qun, W; Ming, H; Xiang-Xin, L; Xue-Liang, C, 2015) |
| "Prognosis of elderly patients with acute myeloid leukemia (AML) remains poor and new treatment approaches are urgently needed." | ( Norkin, M; Richards, AI, 2015) |
| "OCT data were acquired from acute myeloid leukemia (AML) cells treated with cisplatin over a 48-h period." | ( Czarnota, GJ; Farhat, G; Giles, A; Kolios, MC, 2015) |
| "To apply this concept in the context of acute myeloid leukemia and myelodysplasia, we have investigated the overexpression of the multidrug resistance 1 (MDR1) and the cytidine deaminase (CDD) gene conferring resistance to anthracyclines and cytarabine (Ara-C), the two most important drugs in the treatment of these diseases." | ( Brennig, S; Buchegger, T; Hetzel, M; Lachmann, N; Moritz, T; Schambach, A, 2015) |
| "Effective treatment regimens for elderly acute myeloid leukemia (AML) patients harboring internal tandem duplication mutations in the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/ITD) are lacking and represent a significant unmet need." | ( Chang, E; Ganguly, S; Gocke, CD; Konig, H; Levis, M; Rajkhowa, T, 2016) |
| "Sorafenib is used for the treatment of acute myeloid leukemia patients carrying internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-ITD) mutation." | ( Mihaila, RG, 2015) |
| "Children with acute myeloid leukemia (AML) and Down syndrome have high survival rates with intensity-reduced chemotherapeutic regimens, although the optimal balance between dose intensity and treatment toxicity has not been determined." | ( Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S, 2016) |
| "We herein report a case of acute myeloid leukemia (AML) complicated by GCA that manifested during chemotherapy for AML." | ( Akasaka, H; Itoh, K; Itoh, T; Izumi, M; Kodaka, T; Nohda, Y; Sakane, E; Takahashi, T; Tsuji, G; Tsunemine, H; Umeda, R, 2016) |
| "Survival of acute myeloid leukemia (AML) patients, who are unfit for high-dose chemotherapy, has significantly improved with the advent of low-intensity therapeutic regimens (LITR, comprising decitabine, azacitidine, and low-dose cytarabine)." | ( Bainschab, A; Greinix, HT; Krause, R; Quehenberger, F; Sill, H; Wölfler, A; Zebisch, A, 2016) |
| "A 10-year-old boy with FLT3-ITD-positive acute myelogenous leukemia who developed PRES during sorafenib treatment has been presented here." | ( Bayhan, T; Cetin, M; Gumruk, F; Isgandarova, F; Kuskonmaz, B; Tavil, B; Unal, S, 2016) |
| "About 105 consecutive acute myeloid leukemia (AML) patients treated with the same induction-consolidation program between 2004 and 2013 were retrospectively analyzed." | ( Bacigalupo, A; Ballerini, F; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Miglino, M; Minetto, P; Pastori, G; Rebesco, B; Sessarego, M, 2016) |
| "FMS-like tyrosine kinase 3 (FLT3)-mutant acute myeloid leukemia (AML) portends a poor prognosis, and ineffective targeting of the leukemic stem cell (LSC) population remains one of several obstacles in treating this disease." | ( Aplan, PD; Bruner, JK; Duffield, AS; Ghiaur, G; Greenblatt, SM; Jones, RJ; Jung, E; Li, L; Ma, HS; Nguyen, B; Shirley, CM; Small, D, 2016) |
| "If the disease progresses into acute myeloid leukemia (AML), it is often refractory to treatment." | ( Andersson, AK; Bidgoli, M; Ehinger, M; Hyrenius-Wittsten, A; Jonson, T; Lilljebjörn, H; Scheding, S; Sturesson, H, 2016) |
| "Treatment outcomes for acute myeloid leukemia and myelodysplastic syndromes (MDS) remain unsatisfactory despite progress in various types of chemotherapy and hematopoietic stem cell transplantation." | ( Kida, J; Kondo, T; Okamoto, S; Suemori, S; Tohyama, K; Tohyama, Y; Tsujioka, T, 2016) |
| "Pediatric patients under treatment for acute myeloid leukemia (AML) are at high risk for invasive fungal infection (IFI)." | ( Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D; Yasuda, K, 2018) |
| "The patients with newly diagnosed acute myeloid leukemia (except M3) from October 2013 to October 2014 in our hospital were randomly divided into 2 groups: chemotherapy+placebo (CP) group and lenalidomide+chemotherapy (LC) group." | ( Ma, LM; Ruan, LH; Yang, XW; Zhao, XQ, 2016) |
| "A 40's year-old female patient with acute myeloblastic leukemia received high-dose cytarabine(HD-Ara-C)as her third induction therapy." | ( Aoi, M; Kitamura, K; Sakurada, H; Sugimura, Y; Tachi, T; Teramachi, H; Yamamura, M; Yuge, M, 2016) |
| "However, the development of treatment-related acute myeloid leukemia (t-AML) after the usage of this drug is a concern." | ( Feng, DN; Pan, H; Song, L; Sun, LR, 2016) |
| "Despite advances in the treatment of acute myeloid leukemia (AML), relapse and drug resistance frequently occur." | ( Kataoka, K; Koya, J; Kurokawa, M; Morita, K; Nakazaki, K; Sato, T; Sumitomo, Y; Tsuruta-Kishino, T, 2016) |
| "Treatment for acute myeloid leukemia (AML) has not significantly changed in the last decades and new therapeutic approaches are needed to achieve prolonged survival rates." | ( Banús-Mulet, A; Cornet-Masana, JM; Díaz-Beyá, M; Esteve, J; Etxabe, A; Lara-Castillo, MC; Nomdedeu, M; Risueño, RM; Torrente, MÁ, 2016) |
| "Predicting outcomes for patients with acute myeloid leukemia (AML) on the basis of pretreatment predictors has been the cornerstone of management." | ( Andreeff, M; Borthakur, G; Brandt, M; Cortes, J; Daver, N; DiNardo, C; Estrov, Z; Garcia-Manero, G; Huang, X; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Pierce, S; Ravandi, F; Wang, S; Wang, X, 2017) |
| "Patients with acute myeloid leukemia (AML) during induction chemotherapy and those who receive allogeneic hematopoietic stem cell transplantation (HSCT) are at higher risk of invasive fungal infections (IFI)." | ( Audisio, E; Aversa, F; Bruno, B; Busca, A; Candoni, A; Delia, M; Monaco, F; Mordini, N; Pagano, L; Passera, R; Vacca, A, 2016) |
| "The therapy in elderly patients with acute myeloid leukemia (AML) is a big challenge because of poor risk factors and inferior tolerance to intensive chemotherapy." | ( Ding, K; Fu, R; Li, L; Liu, H; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y, 2017) |
| "Current therapy for acute myeloid leukemia (AML) primarily includes high-dose cytotoxic chemotherapy with or without allogeneic stem cell transplantation." | ( Bradley, HL; Bunting, KD; Qu, CK; Sabnis, HS; Tripathi, S; Tse, W; Yu, WM, 2016) |
| "One of the greatest challenges in acute myeloid leukemia (AML) treatment is preventing relapse." | ( Hou, J; Leung, AY; Liang, R; Luo, T; Ng, KL; Sun, D, 2016) |
| "Therapy for acute myeloid leukemia (AML) in elderly populations (>65 years) is still a challenge for scientists and hematologists worldwide, and represents an urgent medical need." | ( Marconi, G; Martinelli, G; Ottaviani, E; Paolini, S; Papayannidis, C; Parisi, S; Sartor, C; Simonetti, G; Tenti, E; Testoni, N, 2016) |
| "Although the majority of patients with acute myeloid leukemia (AML) initially respond to chemotherapy, many of them subsequently relapse, and the mechanistic basis for AML persistence following chemotherapy has not been determined." | ( Abdel-Wahab, O; Arcila, ME; Armstrong, SA; Bastian, L; Chramiec, AG; Cross, JR; Durham, BH; Ganzel, C; Garrett-Bakelman, FE; Gönen, M; Gonzalez, AR; Guryanova, OA; Hoermann, G; Keller, MD; Koche, RP; Krivtsov, AV; Kubicek, S; Levine, RL; Lieu, YK; Loizou, E; Luciani, L; Mason, CE; McKenney, AS; Melnick, AM; Mohanty, A; Mukherjee, S; Nimer, SD; Paietta, EM; Pastore, F; Pronier, E; Rivera, SA; Rowe, JM; Shank, K; Sperr, WR; Spitzer, B; Staber, PB; Tallman, MS; Tovbin, D; Weinstein, AR, 2016) |
| "We report a 3-year old-boy with acute myeloid leukemia (AML)-M7 and vancomycin-resistant enterococcus bacteremia successfully treated with daptomycin." | ( Büyükcam, A; Cengiz, AB; Karadağ Öncel, E; Kuşkonmaz, B; Özsürekçi, Y; Sancak, B, 2016) |
| "Patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations (FLT3-ITD+) who relapse after allogeneic transplantation (allo-SCT) have a very dismal prognosis with the currently available treatment options." | ( Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T, 2017) |
| "Cytarabine (AraC) has been the primary treatment agent for acute myeloid leukemia (AML) in the past 30 years, but the precise mechanism of its action is not completely known." | ( Studzinski, GP; Zheng, R, 2017) |
| "Elderly and infirm patients with acute myeloid leukemia (AML) with either induction refractory or relapse disease may benefit from treatment with azacitidine." | ( Avivi, I; Gatt, M; Helman, I; Inbar, T; Merkel, D; Nagler, A; Ofran, Y; Ram, R, 2017) |
| "The interaction between acute myeloid leukemia cells (AML) with the bone marrow stroma cells (BMSCs) determines a protective environment that favors tumor development and resistance to conventional chemotherapy." | ( Broekhuizen, R; Court, F; Ernst, D; García, P; González, A; Macanas-Pirard, P; Montecinos, VP; Nervi, B; Ocqueteau, M; Oyanadel, C; Ramirez, P, 2017) |
| "For refractory or relapsed acute myeloid leukemia patients, allogeneic hematopoietic stem cell transplantation is the only curative treatment option, but the disease must be in remission before this can be attempted." | ( Cairoli, R; Greco, R; Grillo, G; Mancini, V; Marbello, L; Molteni, A; Ravano, E; Riva, M; Zucchetti, E, 2017) |
| "However, the impact of autophagy on acute myeloid leukemia (AML) maintenance and the validity of autophagy as a viable target in AML therapy remain unclear." | ( Chen, S; Chen, X; Clark, J; Davis, A; Fan, C; Guan, JL; Kumar, A; Mulloy, JC; Wunderlich, M; Zheng, Y, 2017) |
| "Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched in quiescent immature leukemic stem cells (LSC)." | ( Aroua, N; Barreira, Y; Bosc, C; Boutzen, H; Broin, N; Carroll, M; Cassant-Sourdy, S; Castellano, R; Collette, Y; Danet-Desnoyers, G; David, M; de Toni, F; Delhommeau, F; Duchamp, O; Farge, T; Féliu, V; Fraisse, M; Gales, L; Garmy-Susini, BH; Griessinger, E; Hirsch, P; Hosseini, M; Iacovoni, J; Kaoma, T; Larrue, C; Linares, LK; Montersino, C; Nicolau-Travers, ML; Palama, T; Perry, R; Portais, JC; Récher, C; Saland, E; Sarry, A; Sarry, JE; Scotland, S; Selak, M; Serhan, N; Stuani, L; Sugita, M; Tavitian, S; Vallar, L; Vergez, F, 2017) |
| "Outcomes of acute myeloid leukemia (AML) in elderly patients unfit for intensive chemotherapy is challenging." | ( Al-Kali, A; Begna, K; Elliott, M; Hogan, W; Litzow, M; McCullough, K; Nanah, R; Patnaik, M, 2017) |
| "Elderly patients with acute myeloid leukemia (AML) have limited treatment options concerned about their overall fitness and potential treatment related mortality." | ( He, PF; Lian, XY; Lin, J; Ma, JC; Qian, J; Wen, XM; Xu, ZJ; Yao, DM; Zhang, ZH; Zhou, JD, 2017) |
| "Outcomes for children with acute myeloid leukemia (AML) have improved over the past 20 years even though the medications used for induction therapy have not changed." | ( Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L, 2017) |
| "In 6 patients with acute myeloid leukemia or myelodysplastic syndrome and 12 healthy subjects, DAMPs, cytokines, and markers of immunoparalysis were determined before and during the first week after chemotherapy initiation." | ( Blijlevens, NMA; Kox, M; Leijte, GP; Pickkers, PP; Scheffer, GJ; Timmermans, K, 2017) |
| "All adult inpatients with acute myeloid leukemia undergoing chemotherapy, who received posaconazole for invasive fungal infection prophylaxis between 2012 and 2015, were included." | ( Fallon, MJ; Liebenstein, TK; Widmer, KM, 2018) |
| "Standards of care for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy remain undefined." | ( Cho, SH; Choi, YS; Chung, JS; Lee, HS; Lee, WS; Lim, SN; Oh, SB; Park, SW; Shin, HJ, 2017) |
| "Therapy of acute myeloid leukemia in older persons is associated with poor outcomes because of intolerance to intensive therapy, resistant disease and co-morbidities." | ( Beach, CL; Gale, RP; Kambhampati, S; Kew, A; Kumar, R; McCaul, K; Medeiros, BC; Pollyea, DA; Saini, L; Silverman, LR; Vij, R; Wang, X; Zhong, J, 2018) |
| "Induction therapy for acute myeloid leukemia has not changed much since 1973, when the 7 + 3 regimen of cytarabine and daunorubicin was born." | ( Luger, SM, 2017) |
| "Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017." | ( Perl, AE, 2017) |
| "Effective therapy of acute myeloid leukemia (AML) remains an unmet need." | ( Arnovitz, S; Chen, CH; Chen, J; Chen, Y; Cheng, L; Cui, X; Diao, J; Dong, L; Ferchen, K; He, C; Hu, C; Huang, H; Jiang, X; Jin, J; Li, C; Liu, PP; Lu, J; Mulloy, JC; Nie, J; Qin, X; Reinhold, WC; Seibel, W; Shen, C; Skibbe, JR; Su, R; Tang, Y; Ulrich, B; Wang, Y; Weng, H; Wunderlich, M; Zheng, Y; Zuo, Z, 2017) |
| "Treatment for acute myeloid leukemia (AML) has remained relatively unchanged over the past few decades." | ( Evans, AG; Goorha, S; Hobbs, ALV; Leonard, JM; Mills, EL; Seligson, ND, 2018) |
| "A 16-year-old male patient undergoing treatment for acute myeloid leukemia complained of eye pain and blurred vision in his right eye." | ( Hagiwara, S; Kiyota, N; Kunikata, H; Makimura, K; Maruyama, K; Nakazawa, T; Sato, N; Taniuchi, S; Toyokawa, M; Yoshida, M, 2018) |
| "We studied three FLT3 ITD acute myeloid leukemia (AML) patients who relapsed after allogeneic haematopoietic stem cell transplantation (alloHSCT) and received multikinase inhibitor (MKI) sorafenib as part of salvage therapy." | ( Dworacki, G; Jaskula, E; Lange, A; Lange, J; Mordak-Domagala, M; Nowak, D; Sedzimirska, M; Simiczyjew, A, 2018) |
| "Decitabine is widely used in the treatment of acute myeloid leukemia (AML) in elderly patients." | ( Chen, Y; Hong, M; Huang, J; Li, J; Li, S; Lian, Y; Mao, J; Qian, S; Wang, S; Yang, L; Zhang, J; Zhao, H; Zhu, H; Zhu, Y, 2018) |
| "A 43-year-old man with acute myeloid leukemia under chemotherapy developed severe neutropenia and pulmonary aspergillosis due to Aspergillus flavus." | ( Benedetti, E; Campani, D; Di Candio, G; Di Franco, G; Furbetta, N; Guadagni, S; Morelli, L; Mosca, F; Palmeri, M; Petrini, M; Pieroni, E; Tagliaferri, E, 2018) |
| "Cells from patients with acute myeloid leukemia (AML) that remain dormant and protected by stromal cells may escape effects of chemotherapy." | ( Pallis, M; Russell, N; Seedhouse, C; Yu, N, 2018) |
| "A 71-year-old woman, diagnosed with acute myeloid leukemia, was hospitalized for surveillance after induction chemotherapy." | ( Bailleux, C; Gari-Toussaint, M; Gastaud, L; Hasseine, L; Martiano, D; Simon, L, 2018) |
| "To improve the treatment outcomes of acute myeloid leukemia (AML), epigenetic modification has been widely tested and used in recent years." | ( Cheng, B; Fang, Q; Lu, T; Ma, D; Tang, S; Wang, J; Wei, D; Yu, K; Zhe, N; Zhou, Z, 2018) |
| "The majority of patients with acute myeloid leukemia (AML) are older and exhibit a poor prognosis even after intensive therapy." | ( Bohl, SR; Bullinger, L; Rücker, FG, 2018) |
| "Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal, with no satisfactory and standard salvage chemotherapy regimen." | ( Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Sanz, MÁ, 2018) |
| "A 47-year-old Japanese man with acute myeloid leukemia receiving chemotherapy through a totally implantable central venous catheter developed fever and headache." | ( Ichiyama, S; Kitano, T; Matsumura, Y; Nagao, M; Noguchi, T; Takaori-Kondo, A; Yamamoto, M, 2018) |
| "The increasing genomic complexity of acute myeloid leukemia (AML), the most common form of acute leukemia, poses a major challenge to its therapy." | ( Chen, Y; Gao, ZJ; Guo, J; Guo, Y; Herbert, MK; Huang, Y; Kozono, S; Li, X; Lian, X; Lin, J; Lin, YM; Liu, H; Lu, KP; Qiu, C; Tang, M; Tsai, CY; Wang, B; Wu, Y; Xie, J; Yuan, X; Zhou, XZ, 2018) |
| "Drug-resistance is a major problem in acute myeloid leukemia (AML) chemotherapy." | ( Jia, L; Liu, B; Liu, Q; Ma, X; Pan, S; Xiao, Y, 2018) |
| "Therapy for acute myeloid leukemia (AML) involves intense cytotoxic treatment and yet approximately 70% of AML are refractory to initial therapy or eventually relapse." | ( Boileau, M; Eppert, K; Frison, H; Laverdière, I; Minden, MD; Mitchell, A; Neumann, AL; Ng, SWK; Wang, JCY, 2018) |
| "Treatment of acute myeloid leukemia (AML) among the elderly is challenging because of intolerance of intensive therapy and therapy-resistant biology." | ( Advani, AS; Bixby, D; DeAngelo, DJ; Erba, HP; Faderl, S; Fathi, AT; Ho, PA; Jillella, A; Kovacsovics, TJ; Lancet, JE; Levy, MY; O'Meara, MM; Ravandi, F; Stein, AS; Stein, EM; Voellinger, J; Walter, RB, 2018) |
| "Cytarabine (Ara-C), a mainstay of acute myeloid leukemia (AML) treatment, is a prodrug requiring activation to ara-CTP for its antileukemic activity." | ( Cao, X; Crews, KR; Elsayed, AH; Gandhi, V; Lamba, JK; Plunkett, W; Pounds, SB; Ribeiro, RC; Rubnitz, JE, 2018) |
| "However, whether PPI can be used to treat t(8;21) acute myeloid leukemia (AML) cells requires further investigation." | ( Chai, Y; Liu, Y; Si, Y; Xiang, Y; Xu, J; Zhang, T; Zhao, H, 2018) |
| "The treatment of FLT3-positive acute myeloid leukemia has advanced recently with the development of a several FLT3-targeting agents that are either approved or in development." | ( Campbell, P; Thomas, CM, 2019) |
| "Patients with acute myeloid leukemia (AML) treated with intensive chemotherapy may require re-induction based on the evaluation of day 14 bone marrow biopsy." | ( Bae, S; Costa, LJ; Erba, HP; Jamy, O; Papadantonakis, N, 2018) |
| "Patients with acute myelogenous leukemia or myelodysplastic syndrome undergoing induction chemotherapy are at increased risk of invasive fungal infection due to prolonged, severe neutropenia." | ( Ahuja, T; Cirrone, F; Papadopoulos, J; Phillips, K; Siegfried, J, 2019) |
| "Late cardiotoxicity after pediatric acute myeloid leukemia therapy causes substantial morbidity and mortality." | ( Alonzo, T; Aplenc, R; Gamis, A; Gerbing, RB; Getz, KD; Ky, B; Leahy, AB; Leger, KJ; Sack, L; Sung, L; Woods, WG, 2019) |
| "The majority of acute myeloid leukemia (AML) patients have a poor response to conventional chemotherapy." | ( Amarteifio, S; Ang, H; Duarte, D; Hawkins, ED; Kong, IY; Lo Celso, C; Pruessner, G; Ruivo, N, 2019) |
| "TP53 mutated acute myeloid leukemia (AML) responds poorly to chemotherapy and has a short overall survival rate with a median of 5-9 months." | ( Welch, JS, 2018) |
| "Standard therapy for Acute Myeloid Leukemia (AML) is rarely curative, and several suggested improvements have had little success so far." | ( Danilenko, M; Harrison, JS; Nachliely, M; Studzinski, GP; Wang, X, 2019) |
| "A 28-year-old man with acute myeloid leukemia treated with prednisone, tacrolimus, and sorafenib following stem cell transplantation presented with severe bilateral lower extremity claudication." | ( Arain, S; Balanescu, DV; Donisan, T; Gould, KL; Hassan, S; Iliescu, C; Karimzad, K; Kim, P; Lopez-Mattei, J; Palaskas, N; Sudasena, D, 2019) |
| "NF-κB mediates acquired resistance in acute myeloid leukemia (AML) cells treated with DNA-damaging agents." | ( Chen, X; Chen, Y; Fan, Y; Li, D; Luo, Y; Wang, T; Wu, L; Xu, J; Zhang, L; Zhuang, Y, 2019) |
| "Children with acute myeloid leukemia (AML) have a 70% survival rate with treatment regimens containing high doses of cytarabine and anthracyclines and, in some, hematopoietic stem cell transplantation (allo-HSCT)." | ( de Bock, GH; de Bont, E; de Haas, V; De Moerloose, B; Dedeken, L; Denys, B; Kaspers, G; Lammens, T; Reedijk, A; Te Loo, M; Uyttebroeck, A; Van Damme, A; van den Heuvel-Eibrink, MM; Van der Werff-Ten Bosch, J; Zsiros, J, 2019) |
| "For this, we developed an acute myeloid leukemia (AML) mouse model (mice were treated with AML cells C1498 and developed leukemia); these mice then received cytarabine chemotherapy." | ( Friedler, S; Huleihel, M; Kapilushnik, J; Lunenfeld, E; Meese, E; Michailov, Y, 2019) |
| "In first-line treatment of acute myeloid leukemia, the induction chemotherapy aims for a rapid leukemic cell reduction." | ( Banck, JC; Görlich, D, 2019) |
| "Induction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies." | ( Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Li, X; Lin, H; Ma, J; Madlambayan, G; Polin, L; Su, Y; Taub, JW; Wang, G; Wang, Y; White, K; Yang, J, 2019) |
| "Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes." | ( Agresta, SV; Attar, EC; Collins, R; de Botton, S; DiNardo, CD; Frattini, MG; Kantarjian, HM; MacBeth, KJ; Pollyea, DA; See, WL; Stein, AS; Stein, EM; Tallman, MS; Tosolini, A; Xu, Q, 2019) |
| "Consolidation chemotherapy in acute myeloid leukemia (AML) aims at eradicating residual leukemic cells and mostly comprises high-dose cytarabine with or without the addition of anthracyclines, including daunorubicin." | ( Aurelius, J; Ewald Sander, F; Hellstrand, K; Kiffin, R; Martner, A; Möllgård, L; Nilsson, S; Thorén, FB, 2019) |
| "The optimal therapy for patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) who relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear." | ( Chen, J; Deng, L; Fan, Z; Gao, L; Han, M; Huang, F; Huang, X; Jiang, E; Liang, X; Liu, Q; Sun, J; Tang, X; Wang, Y; Wu, B; Wu, D; Xuan, L; Zhang, X, 2019) |
| "In older patients with acute myeloid leukemia, the more frequent presence of biologically inherent therapy-resistant disease and increased comorbidities translate to poor overall survival and therapeutic challenges." | ( Ali, NA; Dhulipala, VC; Djulbegovic, B; Extermann, MT; Kim, J; Komrokji, R; Kuykendall, A; Lancet, JE; Reljic, T; Sehovic, M; Sweet, K; Talati, C, 2020) |
| "Interestingly, the cytotoxicity of acute myeloid leukemia cells was increased by radotinib treatment." | ( Cheon, J; Choi, Y; Heo, SK; Jeong, YK; Jo, JC; Ju, LJ; Koh, S; Min, YJ; Noh, EK; Sung, JY; Yu, HM, 2019) |
| "The survival rate for acute myeloid leukemia remains unacceptably low, in large part owing to resistance to chemotherapy and high rates of relapse." | ( Edwards, H; Ge, Y; Knight, T; Lin, H; Liu, F; Su, Y; Sun, L; Taub, JW; Wang, G; Wang, Y, 2019) |
| "Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments." | ( Ahmed, SO; Aljurf, M; Battipaglia, G; Bazarbachi, A; El Cheikh, J; Legrand, O; Massoud, R; Mohty, M; Youniss, R, 2019) |
| "The pathogenesis of acute myeloid leukemia (AML) involves serial acquisition of mutations controlling several cellular processes, requiring combination therapies affecting key downstream survival nodes in order to treat the disease effectively." | ( Andreeff, M; Burks, JK; Cavazos, A; Chen, J; Dail, M; Daver, N; DiNardo, C; Grant, S; Han, L; Jabbour, E; Jacamo, R; Jin, SS; Kantarjian, HM; Kim, E; Koller, PB; Konopleva, M; Leverson, JD; Mak, DH; Phillips, DC; Rahmani, M; Ruvolo, VR; Sampath, D; Shi, C; Wang, J; Zhang, Q; Zhao, Y, 2020) |
| "Initial therapy for acute myeloid leukemia (AML) remained stagnant for approximately four decades despite advances in improved understanding of pathogenesis and prognostication of the disease." | ( Maakaron, JE; Mims, AS, 2019) |
| "Standard treatment for acute myeloid leukemia (AML) comprises (1) induction therapy with both cytarabine and anthracycline and (2) consolidation therapy that is modified according to patients' conditions, including prognostic factors." | ( Kawamata, N; Umezawa, Y, 2019) |
| "One of the greatest challenges in treating acute myeloid leukemia (AML) is chemotherapy refractory disease." | ( Ast, AM; Blenc, AM; Cogle, CR; Drusbosky, LM; Ge, Y; Geddes, T; Lipten, SD; Madlambayan, GJ; Maywood, M; Miller, R; Ostrov, DA; Pezeshkian, MB; Pompeu, Y; Salgado, AD; Vijay, V; Vue, GS, 2019) |
| "Relapsed acute myeloid leukemia (AML) is a significant post-transplant complication lacking standard treatment and associated with a poor prognosis." | ( Caputo, VS; Gmucova, H; Holubova, M; Jindra, P; Leba, M; Lysak, D, 2019) |
| "Treatment of acute myeloid leukemia (AML) is still a challenge because of common relapses or resistance to treatment." | ( Borutinskaitė, V; Griškevičius, L; Janulis, V; Kaupinis, A; Navakauskienė, R; Valius, M; Vitkevičienė, A; Žučenka, A, 2019) |
| "Treatment of acute myeloid leukemia (AML) in elderly patients remains a great challenge." | ( Dong, Y; Hu, J; Li, J; Li, X; Li, Y; Ren, R; Wu, W; Zhang, Y; Zhu, H, 2019) |
| "Chemotherapy is the main treatment for acute myeloid leukemia (AML), but the cure rates for AML patients remain low, and the notorious adverse effects of chemotherapeutic drugs drastically reduce the life quality of patients." | ( Chien, MH; Chow, JM; Ku, CC; Lee, WJ; Wen, YC; Wu, SY; Yang, SF; Yang, YC, 2019) |
| "Patients with post-MF acute myeloid leukemia (AML) may be treated with curative or noncurative intent, but there is no standard of care." | ( Diamantopoulos, PT; Giannakopoulou, N; Hatzidavid, S; Viniou, NA, 2019) |
| "Primary refractory acute myeloid leukemia (AML) and early recurrence of leukemic cells are among the most difficult hurdles to overcome in the treatment of AML." | ( Chung, W; Cui, J; Han, J; Heo, JY; Jang, Y; Ju, X; Kim, SJ; Kweon, GR; Lee, MJ; Lee, YL; Ryu, MJ; Son, JH; Song, IC, 2019) |
| "Here, we present a case of acute myeloid leukemia (AML) with the development of fungal endophthalmitis during chemotherapy." | ( Fukuhara, N; Harigae, H; Ichikawa, S; Okitsu, Y; Onishi, Y; Onodera, K; Watanabe, S, 2020) |
| "To date, only one subtype of acute myeloid leukemia (AML), acute promyelocytic leukemia (APL) can be effectively treated by differentiation therapy utilizing all-trans retinoic acid (ATRA)." | ( Bens, M; Böhmer, FD; Brioli, A; Ernst, T; Groth, M; Heidel, FH; Hinze, A; Hochhaus, A; Kahl, M; Kresinsky, A; Martinelli, G; Perner, F; Petrie, K; Sbirkov, Y; Schenk, T; Schnetzke, U; Scholl, S; Simonetti, G; Stengel, S; Zelent, A, 2019) |
| "Despite the improvement in acute myeloid leukemia (AML) treatments, most patients had a poor prognosis and suffered from chemoresistance and disease relapse." | ( Ding, Z; Liu, J; Ni, Y; Pan, S; Peng, Y; Wang, S; Wei, Q; Xiao, L; Zhao, W; Zhu, B, 2020) |
| "Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients." | ( Abbott, D; Boggs, C; Chase, S; Ewalt, MD; Gutman, JA; Halsema, K; Jordan, CT; Kaiser, J; Lyle, L; Nakic, M; Pollyea, DA; Purev, E; Rana, V; Rosser, J; Schowinsky, JT; Schuster, S; Siegele, B; Smith, C; Stevens, BM; Tobin, J; Winters, AC, 2019) |
| "Ltd, to develop a new treatment for acute myelogenous leukemia." | ( Gao, X; Hu, X; Hua, H; Li, D; Li, Z; Wang, Y; Xiao, Y; Xu, J; Xu, S; Zang, L, 2020) |
| "We have previously characterized an acute myeloid leukemia (AML) chemotherapy model for SCID-based immune deficient mice (NSG and NSGS), consisting of 5 days of cytarabine (AraC) and 3 days of anthracycline (doxorubicin), to simulate the standard 7+3 chemotherapy regimen many AML patients receive." | ( Byerly, L; Manning, N; Mizukawa, B; Mulloy, JC; O'Brien, E; Perentesis, JP; Sabulski, A; Sexton, C; Wunderlich, M, 2019) |
| "The prognosis for relapsed or refractory acute myeloid leukemia (RR-AML) in children is poor, and the preferred salvage chemotherapy is unclear." | ( Chen, K; Jiang, H; Li, H; Shao, JB; Yang, JW; Zhang, N; Zhu, JS, 2020) |
| "High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment." | ( Akria, L; Ben Yakar, R; Flaishon, L; Gengrinovitch, S; Henig, I; Hoffman, R; Horowitz, NA; Koren-Michowitz, M; Lavi, N; Nudelman, O; Ofran, Y; Ram, R; Rowe, JM; Tavor, S; Tessler, S; Yeganeh, S; Zuckerman, T, 2019) |
| "We included patients treated for acute myeloid leukemia at Brest teaching hospital from January 2009 to December 2015." | ( Baron, R; Berthou, C; Couturier, MA; Guillerm, G; Ianotto, JC; Le Bars, H; Le Clech, L; Narbonne, V; Nevez, G; Payan, C; Quinio, D; Saliou, P; Uguen, M, 2020) |
| "Despite advances in the treatment of acute myeloid leukemia (AML), prognosis of AML patients is still dismal and better treatment options are required." | ( Dittmann, J; Ewald, L; Fulda, S; Vogler, M, 2019) |
| "cerevisiae as drug delivery vehicles for acute myeloid leukemia (AML) treatment." | ( Choi, W; Heo, MY; Kim, SY; Kim, YH; Min, J; Wee, JH, 2020) |
| "Treatment of acute myeloid leukemia (AML) remains inefficient due to drug resistance and relapse, particularly in patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)." | ( Cerella, C; Christov, C; Diederich, M; Ha, YN; Kijjoa, A; Orlikova-Boyer, B; Song, S, 2020) |
| "BACKGROUND Clinical relapse in acute myeloid leukemia (AML) is associated with the reduced treatment response of leukemia stem cells (LSCs)." | ( Han, YJ; Li, Y; Liu, H; Tang, YL; Wang, CL; Wang, YP; Zhang, CG; Zhou, Y, 2020) |
| "Complete response was then achieved with acute myeloid leukemia therapy followed by unrelated donor umbilical cord allogenic stem cell transplant." | ( Amador, C; Fu, K; Lowas, S; Patel, SA; Perry, DA; Pirruccello, SJ; Turcotte, K, 2021) |
| "Despite the approval of 8 new drugs for acute myeloid leukemia (AML) since 2017, the disease remains challenging, given the significant toxicity associated with available treatments and relatively low cure rates, especially in older adults." | ( Burnett, A; Stone, R, 2020) |
| "The treatment of acute myeloid leukemia (AML) is adjusted according to cytogenetic risk factors and molecular markers." | ( Arnan, M; Bargay, J; Coll, R; Cruz, D; Díaz-Santa, J; Escoda, L; Esteve, J; Gallardo, D; Garcia, A; Garrido, A; Heras, I; Lloveras, N; Moret, C; Osca, G; Pratcorona, M; Quiñones, T; Rodríguez-Romanos, R; Salamero, O; Sampol, A; Sierra, J; Tormo, M; Vives, S, 2020) |
| "Venetoclax is a promising agent in the treatment of acute myeloid leukemia, though its antileukemic activity is limited to combination therapies." | ( Dzinic, SH; Edwards, H; Ge, Y; Hege, K; Knight, T; Kushner, J; Li, X; Lin, H; Madlambayan, G; Miller, R; Polin, L; Su, Y; Taub, JW; Wang, G; Wang, Y; White, K; Yang, J; Zhao, L, 2021) |
| "A principal challenge in treating acute myeloid leukemia (AML) is chemotherapy refractory disease." | ( Floren, M; Gillette, JM; Lidke, KA; Marjon, KD; Restrepo Cruz, S; Termini, CM, 2020) |
| "Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II α and topo IIβ." | ( Advani, AS; Appelbaum, FR; Ganapathi, MK; Ganapathi, RN; Godwin, JE; Koegle, ER; List, AF; McDonough, S; Michelson, AP; Othus, M; Petersdorf, SH; Radich, JP; Willman, CL, 2020) |
| "Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT)." | ( Agrawal, V; Arain, S; Cahill, K; Calip, GS; Christian, S; Esen, A; Griffin, S; Khan, I; Konig, H; Odenike, O; Patel, P; Quigley, JG; Shergill, A; Stock, W; Sweiss, K, 2020) |
| "Among elderly patients with acute myeloid leukemia (AML), especially those who are unfit for intensive chemotherapy, a policy of reduced-intensity chemotherapy or conservative observation has been chosen, resulting in unmet medical needs." | ( Naoe, T, 2020) |
| "We report an elderly acute myeloid leukemia patient with a complex karyotype who received a reduced dose of decitabine in induction chemotherapy due to a combination of severe heart disease." | ( Liu, C; Shao, Z; Sun, Y; Wu, C, 2020) |
| "Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent." | ( DiNardo, CD; Döhner, H; Esteve, J; Fenaux, P; Garcia, JS; Hájek, R; Havelange, V; Hong, WJ; Illés, Á; Jang, JH; Jonas, BA; Koller, E; Konopleva, M; Lavie, D; Leber, B; Lemoli, RM; Letai, A; Pejsa, V; Porkka, K; Potluri, J; Pratz, KW; Pullarkat, V; Thirman, MJ; Turgut, M; Wang, J; Wei, AH; Yamamoto, K; Yeh, SP; Yoon, SS; Zhou, Y, 2020) |
| "Chemotherapy is the main approach for treating acute myeloid leukemia (AML)." | ( Hu, MH; Jin, G; Wang, X; Yu, BY, 2020) |
| "In pediatric acute myeloid leukemia (AML), intensive chemotherapy and allogeneic hematopoietic stem cell transplantation are the cornerstones of treatment in high-risk cases, with severe late effects and a still high risk of disease recurrence as the main drawbacks." | ( Benetton, M; Borella, G; Borile, G; Buldini, B; Campello, S; Cogo, P; Da Ros, A; Locatelli, F; Massi, A; Minuzzo, S; Pigazzi, M; Polato, K; Porcù, E; Romagnoli, R; Simonato, M; Simula, L; Tregnago, C, 2020) |
| "Recent evidence demonstrated that the treatment of acute myeloid leukemia (AML) cells with daunorubicin (DNR) but not cytarabine (Ara-C) results in immunogenic cell death (ICD)." | ( Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR, 2020) |
| "Refractory acute myeloid leukemia (AML) remains a challenging hematological malignancy to treat, due to the development of drug resistance, severe complications, and relapse in chemotherapies." | ( Ge, Y; Lai, X; Liu, J; Meng, J; Wang, J; Wei, H; Wen, T; Xu, H; Xu, S; Yan, D; Zhang, W, 2020) |
| "Consolidation treatment in acute myeloid leukemia (AML) patients achieving complete remission (CR) is warranted." | ( Archetti, S; Bellotti, D; Bertoli, D; Borlenghi, E; Carbone, C; Cattaneo, C; Cerqui, E; Crippa, C; Dalceggio, D; Farina, M; Gramegna, D; Oberti, M; Pagani, C; Passi, A; Rossi, G; Schieppati, F; Sciumé, M; Soverini, G; Tucci, A, 2020) |
| "The prognosis of children with acute myeloid leukemia (AML) has improved with the efficacy of hematopoietic cell transplantation (HCT) as a second-line therapy and improvements in supportive care following anthracycline- and cytarabine-based chemotherapy; however, the outcomes of children with relapsed AML still remain unsatisfactory." | ( Adachi, S; Goto, H; Hasegawa, D; Iwamoto, S; Kakuda, H; Koh, K; Miyamura, T; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D; Yuza, Y, 2021) |
| "Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT)." | ( Alati, C; Audisio, E; Bertani, G; Bilio, A; Caizzi, M; Candoni, A; Carnevale-Schianca, F; Cerrano, M; Cignetti, A; Clavio, M; D'Ardia, S; Dargenio, M; Ferrara, F; Fianchi, L; Fracchiolla, N; Galimberti, S; Gottardi, M; Grimaldi, F; Guolo, F; Gurreri, C; Lemoli, RM; Minetto, P; Morselli, M; Musto, P; Pagano, L; Pasciolla, C; Pavesi, F; Pietrantuono, G; Rizzuto, G; Rondoni, M; Rossi, G; Scappini, B; Scattolin, AM; Tafuri, A; Zappasodi, P, 2020) |
| "Conventional therapy for acute myeloid leukemia is composed of remission induction with cytarabine- and anthracycline-containing regimens, followed by consolidation therapy, including allogeneic stem cell transplantation, to prolong remission." | ( Daver, N; DiNardo, CD; Fathi, AT; Pollyea, DA; Vyas, P; Wei, AH, 2020) |
| "Our patient was a 4-year-old female with acute myeloid leukemia complicated with right calcaneal osteomyelitis due to Mycobacterium abscessus with subcutaneous abscesses extending to the popliteal and groin regions after two courses of induction chemotherapy according to NOPHO-AML 2012 protocol." | ( Chan, WY; Ha, SY; Ho, KW; Ho, PL; Lam, AY; Lau, TW; So, NL; To, KK, 2021) |
| "Complex karyotype acute myeloid leukemia (CK-AML) has a dismal outcome with current treatments, underscoring the need for new therapies." | ( Baer, MR; Bhandary, B; Bollino, D; Carter-Cooper, B; Chang, E; Choi, EY; Civin, CI; Emadi, A; Gartenhaus, RB; Kaizer, H; Kamangar, F; Kapadia, B; Lapidus, RG; Ma, X; Mahurkar, A; Moses, BS; Niyongere, S; Shetty, AC; Strovel, ET; Tighe, KM, 2021) |
| "Induction therapy for acute myeloid leukemia (AML) is an anthracycline-based chemotherapy regimen." | ( Chen, XS; Dou, LP; Gao, CJ; Li, YH; Liu, DH; Liu, SJ; Liu, YC; Pang, BX; Wang, H; Wang, MZ; Wang, XK; Yan, F; Zhu, CY, 2020) |
| "In an acute myeloid leukemia (AML) mouse model, we demonstrated that the liquid nitrogen-treated AML cells (LNT cells) can augment targeted delivery of doxorubicin (DOX) toward the bone marrow." | ( Abdou, P; Chen, G; Ci, T; Dotti, G; Gu, Z; Li, H; Tu, Y; Wang, J; Wang, Z, 2020) |
| "With novel treatment strategies for acute myeloid leukemia becoming more readily utilized in the clinical practice setting, new data on potential treatment-related adverse events also has become available." | ( Chiang, T; Miller, C; Seabury, R; Triesel, K, 2021) |
| "A 65-year-old man with acute myeloid leukemia 6 was treated by bone marrow allograft, developed a systemic classic chronic graft versus host disease with hepatic, rheumatologic, ophthalmic, and muco-cutaneous involvement." | ( Adas, A; Arnault, JP; Attencourt, C; Chaby, G; Charbonnier, A; Cohen-Sors, R; Lok, C, 2020) |
| "Venetoclax was approved in 2018 for the treatment of acute myeloid leukemia (AML) patients who were not suitable for high-dose chemotherapy." | ( Lin, N; Wang, L, 2021) |
| "He was diagnosed with concurrent acute myeloid leukemia and multiple myeloma without history of chemotherapy." | ( Albayrak, M; Falay, M; Han, U; Maral, S; Ozturk, HBA; Sahin, O, 2021) |
| "ICI therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after alloHCT may be a safe and feasible option." | ( Abdel-Wahab, N; Abudayyeh, A; Al-Atrash, G; Alousi, AM; Champlin, R; Daher, M; Daver, N; Diab, A; Fa'ak, F; Garcia-Manero, G; Gruschkus, S; Gulbis, AM; Joseph, J; Knape, C; Konopleva, M; Ludford, K; Marcotulli, M; Mehta, R; Ohanian, M; Oran, B; Popat, UR; Rafei, H; Ravandi, F; Rondon, G; Saberian, C; Safa, H; Shoukier, M; Suarez-Almazor, ME; Whited, L, 2021) |
| "The treatment of acute myeloid leukemia (AML) has evolved considerably over the past several years." | ( Konopleva, M; Saxena, K, 2021) |
| "For more than 30 years, treatment of acute myeloid leukemia (AML) has remained largely unchanged and reliant on chemotherapeutic drug combinations, specifically cytarabine and daunorubicin (the 7 + 3 regimen)." | ( Anantha, M; Bally, MB; Chen, KTJ; Leung, AWY; Militao, GGC; Witzigmann, D, 2021) |
| "Relapse in acute myeloid leukemia (AML) is common, especially in older patients, and there is currently no standard of care maintenance therapy for those who achieve complete remission." | ( Craddock, C; de Lima, M; Ossenkoppele, G; Platzbecker, U; Roboz, GJ, 2021) |
| "that describes potential risk of acute myeloid leukemia or myeloproliferative disorder among thiopurine therapy." | ( Ha, C, 2021) |
| "In pediatric acute myeloid leukemia (AML), chemotherapy is the standard of care, but >30% of patients still relapse." | ( Benetton, M; Bisio, V; Borella, G; Borile, G; Bresolin, S; Buldini, B; Cairo, S; Campodoni, E; Cani, A; Da Ros, A; Leszl, A; Locatelli, F; Marchetti, A; Michielotto, B; Montesi, M; Montini, B; Pigazzi, M; Porcù, E; Sandri, M; Tregnago, C, 2021) |
| "Elderly and/or unfit patients with acute myeloid leukemia have historically been challenging to manage as they were ineligible for what was considered standard of care treatment with induction chemotherapy." | ( Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME, 2021) |
| "Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes." | ( Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME, 2021) |
| "Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy." | ( Borthakur, G; Kantarjian, H, 2021) |
| "Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have limited treatment options." | ( Alexander, L; Andreeff, M; Borthakur, G; Bueso-Ramos, C; Cheung, CM; Daver, N; DiNardo, CD; Garcia-Manero, G; Herbrich, SM; Jabbour, E; Kadia, TM; Konopleva, MY; Kornblau, S; Loghavi, S; Pemmaraju, N; Pierce, SA; Ravandi, F; Saxena, K; Tang, G; Wang, SA, 2021) |
| "Patients receiving chemotherapy for acute myeloid leukemia (AML) are at high risk for invasive fungal disease (IFD)." | ( Alexander, S; Boge, CLK; Dvorak, CC; Esbenshade, AJ; Fisher, BT; Gunn, S; Nieder, M; Sung, L; Villaluna, D; Westling, T; Wheat, LJ; Wingard, JR; Zaoutis, TE; Zerr, DM, 2021) |
| "Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal." | ( Bailey, R; Beach, CL; Chevassut, T; Döhner, H; Dombret, H; Figuera-Alvarez, A; Hiwase, D; La Torre, I; Montesinos, P; Musso, M; Pierdomenico, F; Pocock, C; Ravandi, F; Roboz, GJ; Safah, H; Sayar, H; Selleslag, D; Skikne, B; Sohn, SK; Tse, W; Wei, AH; Zhong, J, 2021) |
| "The poor outcomes in acute myeloid leukemia (AML) necessitate new treatments." | ( Bao, S; Deng, Q; Zhang, C; Zhu, J, 2021) |
| "Survival for older patients with acute myeloid leukemia (AML) unsuitable for intensive chemotherapy is unsatisfactory." | ( Ariti, C; Burnett, AK; Clark, RE; Copland, M; Dennis, M; Gilkes, A; Hemmaway, C; Hills, RK; Knapper, S; Mehta, P; Radia, R; Russell, N; Thomas, IF; Upton, L, 2021) |
| "The treatment landscape for acute myeloid leukemia has expanded significantly in the past 5 years with the approval of several therapeutic small molecules." | ( Daver, N; DiNardo, C; Konopleva, M; Saxena, K, 2022) |
| "Several attempts have been made to treat non-APL acute myeloid leukemia (AML) patients by employing differentiation inducers, such as hypomethylating agents and low-dose cytarabine, with encouraging results." | ( Takahashi, S, 2022) |
| "Therapy-related acute myeloid leukemia (t-AML) is a well-recognized clinical syndrome occurring in a significant fraction of patients who have undergone previous chemotherapy for a solid tumour." | ( Minari, JB; Ndiokwelu, UF; Ogunkanmi, LA; Uzoma, IC, 2021) |
| "Pediatric acute myeloid leukemia (AML) is a challenging disease to treat in low- and middle-income countries (LMICs)." | ( Kaspers, GJL; Kipng'etich, M; Klein, K; Langat, S; Mostert, S; Njuguna, F; Olbara, G; van Weelderen, RE; Vik, TA, 2022) |
| "Current therapy in acute myeloid leukemia (AML) is based on chemotherapeutic drugs administered at high doses, lacking targeting selectivity and displaying poor therapeutic index because of severe adverse effects." | ( Álamo, P; Alba-Castellón, L; Aviñó, A; Casanova, I; Cedó, L; Eritja, R; Falgàs, A; Gallardo, A; García-León, A; Mangues, R; Núñez, Y; Pallarès, V; Sánchez-García, L; Serna, N; Sierra, J; Unzueta, U; Vázquez, E; Villaverde, A, 2022) |
| "Treatment of acute myeloid leukemia (AML) remains challenging and novel targets and synergistic therapies still need to be discovered." | ( Agelopoulos, K; Berdel, WE; Göllner, S; Klosner, J; Müller-Tidow, C; Rohde, C; Schliemann, C, 2021) |
| "An interaction between acute myeloid leukemia (AML) cells and endothelial cells in the bone marrow seems to play a critical role in chemosensitivity on leukemia treatment." | ( Itsumi, M; Kajikawa, M; Kato, H; Kawai, C; Kitakaze, K; Kuribayashi, F; Miyano, K; Okamoto, S; Yamauchi, A, 2022) |
| "A relative wealth of new therapies for acute myeloid leukemia (AML) have led to a rapid shift in treatment paradigms for this disease." | ( Kasner, M; Wilde, L, 2021) |
| "The treatment of patients with acute myeloid leukemia (AML) who are intolerable to intensive chemotherapy remains to be further explored." | ( Kuang, P; Liu, T; Qin, Y, 2023) |
| "Throughout the clinical course of acute myeloid leukemia (AML), aspergillosis infection remains a significant determinant of treatment outcomes and survival." | ( Bae, NY; Byun, JM; Choe, PG; Kang, CK; Kim, MS; Kim, NJ; Park, KJ; Yoon, SS, 2022) |
| "Patients with acute myeloid leukemia (AML) unfit for, or resistant to, intensive chemotherapy are often treated with DNA methyltransferase inhibitors (DNMTi)." | ( Baer, MR; Baylin, SB; Bentzen, SM; Duong, VH; Emadi, A; Kogan, AA; Lapidus, RG; Mi, T; Niyongere, S; O'Connell, CL; Rassool, FV; Youngblood, BA, 2022) |
| "Treated secondary acute myeloid leukemia (ts-AML)-i." | ( Al-Atrash, G; Borthakur, G; Champlin, RE; Daver, N; Dinardo, CD; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Macaron, W; Maiti, A; Mehta, R; Montalban-Bravo, G; Oran, B; Popat, U; Qiao, W; Ravandi, F; Short, NJ; Shpall, EJ; Venugopal, S; Yilmaz, M, 2022) |
| "Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for 7 %-8 % of AML cases and primarily occurs in elderly patients." | ( Strickland, SA; Vey, N, 2022) |
| "The clinical outcomes of patients with acute myeloid leukemia (AML) treated with available therapy remain unsatisfactory." | ( Bhandary, B; Bollino, D; Eckert, RL; Emadi, A; Gartenhaus, RB; Kapadia, B; Lapidus, RG; Mahmood, K; Mahurkar, A; Shetty, AC, 2022) |
| "Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2-selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance." | ( Andreeff, M; Baran, N; Battula, VL; Bueso-Ramos, CE; Cai, T; Davis, RE; DiNardo, CD; Dunner, K; Ganesan, S; Ghosh, S; Grosskurth, SE; Han, L; Jia, Y; Jitkova, Y; Konoplev, SN; Konopleva, M; Kurtz, S; Letai, A; Leverson, J; Lodi, A; Lu, C; Ma, H; Ma, W; Mi, Y; Padua, RA; Pan, R; Popovic, R; Ramage, CL; Riley-Gillis, B; Ruvolo, VR; Ryan, JA; Schimmer, A; Shi, C; Sweeney, SR; Tiziani, S; Tyner, JW; Vijay, P; Wang, J; Weng, CC; Zhang, H; Zhang, Q, 2022) |
| "Relapsed/refractory (R/R) acute myeloid leukemia (AML) that is ineligible for aggressive chemotherapy regimens and allogeneic hematopoietic stem-cell transplantation has an extremely poor prognosis." | ( He, J; Liu, F; Wang, N, 2022) |
| "The clinical therapeutic regimen for acute myeloid leukemia (AML) is not significantly different between adults and children, which is mostly based on IA (idarubicin and cytosine arabinoside) induction chemotherapy." | ( DU, CK; Lu, Y, 2022) |
| "Newly diagnosed acute myeloid leukemia is often deemed a medical emergency, requiring urgent treatment." | ( Borthakur, G; Brandt, M; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Kim, K; Konopleva, M; Loghavi, S; Pemmaraju, N; Pierce, S; Rausch, CR; Ravandi, F; Sasaki, K; Short, NJ; Tang, G; Yilmaz, M, 2022) |
| "The treatment of acute myeloid leukemia (AML) is developing towards "targeted therapy", which faces challenges such as low sensitivity and drug resistance." | ( Cao, S; Hussain, Z; Liu, H; Xie, Q; Yan, X; Zeng, C; Zhou, G, 2022) |
| "Treatment of elderly patients with acute myeloid leukemia is a known challenge for hematologists due to patient diversity, heterogeneous disease biology, and a rapidly evolving treatment landscape." | ( de Leeuw, DC; Janssen, JJWM; Ossenkoppele, GJ, 2022) |
| "The treatment of acute myeloid leukemia (AML) with unfavorable cytogenetics treatment remains a challenge." | ( Bay, JO; Béné, MC; Bertrand, P; Bonmati, C; Carré, M; Darrouzain, F; Gallego-Hernanz, MP; Gyan, E; Hérault, O; Hunault, M; Lioure, B; Peterlin, P; Picou, F; Pigneux, A; Récher, C; Ternant, D; Vallet, N, 2022) |
| "Recently new treatments for acute myeloid leukemia (AML) emerged, including regimens like CPX-351 and cladribine with cytarabine and daunorubicin (DA + C), demonstrating improved survival in patient subsets." | ( Alsdorf, WH; Bokemeyer, C; Brauneck, F; Fiedler, W; Ghandili, S; Karagiannis, P; Klingler, F; Modemann, F; Wolschke, C, 2022) |
| "In a retrospective analysis, 21 acute myeloid leukemia patients receiving single-agent sorafenib maintenance therapy in complete remission (CR) after hematopoietic stem cell transplantation (HSCT) were compared with a control group of 22 patients without maintenance." | ( Aydin, S; Brunello, L; Busca, A; Cattel, F; Dellacasa, CM; Dogliotti, I; Giaccone, L; Passera, R; Poggiu, M; Scaldaferri, M; Zallio, F, 2022) |
| "Leukemic stem cells in acute myeloid leukemia (AML) express high B cell lymphoma 2 (BCL2) levels, which contribute to leukemic cell survival and resistance to therapy." | ( Fujita, N; Kameoka, Y; Kitadate, A; Kobayashi, T; Miura, M; Nara, M; Sato, H; Takahashi, N; Yamashita, T; Yoshioka, T, 2022) |
| "Patients with Acute Myeloid Leukemia (AML) have a complex disease trajectory characterized by high symptom and psychosocial burden, a high rate of hospitalization and intensive care unit admission at the end-of-life (EOL), and frequent use of chemotherapy near the EOL." | ( Koets, V; Montagnini, M, 2023) |
| "RUNX1-mutated (mRUNX1) acute myeloid leukemia (AML) has historically been associated with poor outcomes in the setting of conventional chemotherapy." | ( Bhalla, K; Borthakur, G; Chien, K; Daver, N; DiNardo, CD; Issa, GC; Jabbour, E; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Loghavi, S; Macaron, W; Maiti, A; Montalban-Bravo, G; Patel, KP; Qiao, W; Ravandi, F; Short, NJ; Venugopal, S; Yilmaz, M, 2022) |
| "Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical trials are actively exploring the role of venetoclax in combination with intensive chemotherapy in fitter patients with AML." | ( Adams, JM; Anstee, NS; Banquet, S; Blombery, P; Brown, FC; Chua, CC; Dengler, MA; Dun, K; Halilovic, E; Herold, MJ; Huang, DCS; Lessene, G; Litalien, V; MacRaild, S; Morley, T; Morris, E; Morris, R; Moujalled, DM; Pomilio, G; Roberts, AW; Shah, J; Thompson, E; Tiong, IS; Wei, AH; Zordan, A, 2023) |
| "One year after patient gave up treatment, acute myeloid leukemia (AML) was confirmed by bone marrow examinations." | ( Chen, Y; Deng, K; Ju, W; Li, L; Ni, W; Wang, L, 2022) |
| "Treatment for acute myeloid leukemia (AML) typically involves intensive chemotherapy (IC); however, there is an unmet need for approximately 50% of AML patients who are deemed unfit or ineligible for IC." | ( Au, Y; Bui, CN; Chai, X; Guinan, K; Lachaine, J; Mathurin, K; Schuh, AC, 2022) |
| "Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are devastating diseases that frequently rely on the use of parenteral hypomethylating agents (HMAs), either as monotherapy or in combination, as first-line treatment for many patients." | ( Feld, J; Navada, SC; Silverman, LR; Tremblay, D, 2023) |
| "Treatment of acute myeloid leukemia (AML) with chemotherapeutic agents fails to eliminate leukemia stem cells (LSC)，and thus patients remain at high risk for relapse." | ( Deng, M; Fang, Z; Huang, Y; Jiang, Y; Lai, Q; Luo, Y; Pan, G; Qin, D; Tan, J; Tang, Y; Xie, C; Xu, B; Zha, J; Zhao, H; Zhong, M; Zhou, H; Zhou, Y, 2023) |
| "Treatment of acute myeloid leukemia (AML) with chemotherapeutic agents fails to eliminate leukemia stem cells (LSC)，and thus patients remain at high risk for relapse." | ( Deng, M; Fang, Z; Huang, Y; Jiang, Y; Lai, Q; Luo, Y; Pan, G; Qin, D; Tan, J; Tang, Y; Xie, C; Xu, B; Zha, J; Zhao, H; Zhong, M; Zhou, H; Zhou, Y, 2023) |
| "Treatment of acute myeloid leukemia (AML) with chemotherapeutic agents fails to eliminate leukemia stem cells (LSC)，and thus patients remain at high risk for relapse." | ( Deng, M; Fang, Z; Huang, Y; Jiang, Y; Lai, Q; Luo, Y; Pan, G; Qin, D; Tan, J; Tang, Y; Xie, C; Xu, B; Zha, J; Zhao, H; Zhong, M; Zhou, H; Zhou, Y, 2023) |
| "MDS treatment is often inspired by treatment for acute myeloid leukemia (AML)." | ( Blum, S; Bresser, H; Lübbert, M; Tsilimidos, G, 2023) |
| "MDS treatment is often inspired by treatment for acute myeloid leukemia (AML)." | ( Blum, S; Bresser, H; Lübbert, M; Tsilimidos, G, 2023) |
| "A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or relapse after achieving remission." | ( Stelmach, P; Trumpp, A, 2023) |
| "Previously, untreated patients with acute myeloid leukemia who were ineligible for intensive chemotherapy were enrolled according to the VIALE-C criteria." | ( Ando, J; Asada, N; Dobashi, N; Honda, H; Iida, H; Ishizawa, K; Miyamoto, T; Mukai, H; Nishimura, Y; Okubo, S; Shinagawa, A; Soshin, T; Takada, S; Tsutsui, A; Usuki, K; Yamamoto, K; Yoshida, C, 2023) |
| "TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available treatments, including venetoclax-based drug combinations and pose a major therapeutic challenge." | ( Andreeff, M; Ayoub, E; Boettcher, S; Carter, BZ; Haferlach, T; Huang, X; Hughes, PE; Kornblau, S; Loghavi, S; Mak, PY; Morrow, PK; Muftuoglu, M; Nishida, Y; Ostermann, LB; Ruvolo, V; Tao, W, 2023) |
| "Current therapy for acute myeloid leukemia (AML) is largely hindered by the development of drug resistance of commonly used chemotherapy drugs, including cytarabine, daunorubicin, and idarubicin." | ( Feng, B; Fu, JF; Kan, WJ; Li, J; Li, JN; Liu, MM; Luo, GH; Song, N; Tu, YT; Wang, HL; Wei, G; Wu, WB; Xu, GY; Xu, R; Zhou, YB, 2023) |
| "Therapy options for relapsed/refractory acute myelogenous leukemia (AML) are limited." | ( Chang, WI; MacDonell-Yilmaz, RE; Moynihan, L; Sampino, EV; Sprinz, PG, 2023) |